{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0b790f6a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: unstructured[all-docs] in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (0.17.2)\n",
      "Requirement already satisfied: chardet in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (5.2.0)\n",
      "Requirement already satisfied: filetype in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.2.0)\n",
      "Requirement already satisfied: python-magic in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (0.4.27)\n",
      "Requirement already satisfied: lxml in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (5.3.1)\n",
      "Requirement already satisfied: nltk in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (3.9.1)\n",
      "Requirement already satisfied: requests in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (2.32.3)\n",
      "Requirement already satisfied: beautifulsoup4 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (4.13.3)\n",
      "Requirement already satisfied: emoji in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (2.14.1)\n",
      "Requirement already satisfied: dataclasses-json in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (0.6.7)\n",
      "Requirement already satisfied: python-iso639 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (2025.2.18)\n",
      "Requirement already satisfied: langdetect in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.0.9)\n",
      "Requirement already satisfied: numpy in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.26.4)\n",
      "Requirement already satisfied: rapidfuzz in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (3.12.2)\n",
      "Requirement already satisfied: backoff in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (2.2.1)\n",
      "Requirement already satisfied: typing-extensions in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (4.12.2)\n",
      "Requirement already satisfied: unstructured-client in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (0.31.1)\n",
      "Requirement already satisfied: wrapt in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.17.2)\n",
      "Requirement already satisfied: tqdm in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (4.67.1)\n",
      "Requirement already satisfied: psutil in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (6.1.1)\n",
      "Requirement already satisfied: python-oxmsg in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (0.0.2)\n",
      "Requirement already satisfied: html5lib in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.1)\n",
      "Requirement already satisfied: onnxruntime>=1.19.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.19.2)\n",
      "Requirement already satisfied: python-pptx>=1.0.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.0.2)\n",
      "Requirement already satisfied: effdet in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (0.4.1)\n",
      "Requirement already satisfied: pypandoc in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.15)\n",
      "Requirement already satisfied: pikepdf in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (9.5.2)\n",
      "Requirement already satisfied: google-cloud-vision in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (3.10.0)\n",
      "Requirement already satisfied: unstructured.pytesseract>=0.3.12 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (0.3.15)\n",
      "Requirement already satisfied: pdfminer.six in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (20240706)\n",
      "Requirement already satisfied: unstructured-inference>=0.8.10 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (0.8.10)\n",
      "Requirement already satisfied: xlrd in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (2.0.1)\n",
      "Requirement already satisfied: networkx in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (3.3)\n",
      "Requirement already satisfied: pandas in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (2.2.3)\n",
      "Requirement already satisfied: pdf2image in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.17.0)\n",
      "Requirement already satisfied: openpyxl in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (3.1.5)\n",
      "Requirement already satisfied: python-docx>=1.1.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.1.2)\n",
      "Requirement already satisfied: pypdf in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (5.4.0)\n",
      "Requirement already satisfied: onnx>=1.17.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (1.17.0)\n",
      "Requirement already satisfied: markdown in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (3.7)\n",
      "Requirement already satisfied: pi-heif in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured[all-docs]) (0.22.0)\n",
      "Requirement already satisfied: protobuf>=3.20.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnx>=1.17.0->unstructured[all-docs]) (5.29.3)\n",
      "Requirement already satisfied: coloredlogs in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnxruntime>=1.19.0->unstructured[all-docs]) (15.0.1)\n",
      "Requirement already satisfied: flatbuffers in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnxruntime>=1.19.0->unstructured[all-docs]) (25.1.24)\n",
      "Requirement already satisfied: packaging in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnxruntime>=1.19.0->unstructured[all-docs]) (24.2)\n",
      "Requirement already satisfied: sympy in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnxruntime>=1.19.0->unstructured[all-docs]) (1.13.1)\n",
      "Requirement already satisfied: Pillow>=3.3.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from python-pptx>=1.0.1->unstructured[all-docs]) (11.1.0)\n",
      "Requirement already satisfied: XlsxWriter>=0.5.7 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from python-pptx>=1.0.1->unstructured[all-docs]) (3.2.2)\n",
      "Requirement already satisfied: python-multipart in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (0.0.20)\n",
      "Requirement already satisfied: huggingface-hub in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (0.30.1)\n",
      "Requirement already satisfied: opencv-python!=4.7.0.68 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (4.11.0.86)\n",
      "Requirement already satisfied: matplotlib in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (3.10.1)\n",
      "Requirement already satisfied: torch in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (2.6.0)\n",
      "Requirement already satisfied: timm in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (1.0.12)\n",
      "Requirement already satisfied: transformers>=4.25.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (4.47.1)\n",
      "Requirement already satisfied: scipy in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (1.15.1)\n",
      "Requirement already satisfied: pypdfium2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-inference>=0.8.10->unstructured[all-docs]) (4.30.1)\n",
      "Requirement already satisfied: soupsieve>1.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from beautifulsoup4->unstructured[all-docs]) (2.6)\n",
      "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from dataclasses-json->unstructured[all-docs]) (3.26.0)\n",
      "Requirement already satisfied: typing-inspect<1,>=0.4.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from dataclasses-json->unstructured[all-docs]) (0.9.0)\n",
      "Requirement already satisfied: torchvision in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from effdet->unstructured[all-docs]) (0.21.0)\n",
      "Requirement already satisfied: pycocotools>=2.0.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from effdet->unstructured[all-docs]) (2.0.8)\n",
      "Requirement already satisfied: omegaconf>=2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from effdet->unstructured[all-docs]) (2.3.0)\n",
      "Requirement already satisfied: google-api-core!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.1->google-cloud-vision->unstructured[all-docs]) (2.24.2)\n",
      "Requirement already satisfied: google-auth!=2.24.0,!=2.25.0,<3.0.0dev,>=2.14.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-cloud-vision->unstructured[all-docs]) (2.38.0)\n",
      "Requirement already satisfied: proto-plus<2.0.0dev,>=1.22.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-cloud-vision->unstructured[all-docs]) (1.26.1)\n",
      "Requirement already satisfied: six>=1.9 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from html5lib->unstructured[all-docs]) (1.17.0)\n",
      "Requirement already satisfied: webencodings in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from html5lib->unstructured[all-docs]) (0.5.1)\n",
      "Requirement already satisfied: click in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from nltk->unstructured[all-docs]) (8.1.8)\n",
      "Requirement already satisfied: joblib in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from nltk->unstructured[all-docs]) (1.4.2)\n",
      "Requirement already satisfied: regex>=2021.8.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from nltk->unstructured[all-docs]) (2024.11.6)\n",
      "Requirement already satisfied: et-xmlfile in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from openpyxl->unstructured[all-docs]) (2.0.0)\n",
      "Requirement already satisfied: python-dateutil>=2.8.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pandas->unstructured[all-docs]) (2.9.0.post0)\n",
      "Requirement already satisfied: pytz>=2020.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pandas->unstructured[all-docs]) (2024.2)\n",
      "Requirement already satisfied: tzdata>=2022.7 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pandas->unstructured[all-docs]) (2025.1)\n",
      "Requirement already satisfied: charset-normalizer>=2.0.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pdfminer.six->unstructured[all-docs]) (3.4.1)\n",
      "Requirement already satisfied: cryptography>=36.0.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pdfminer.six->unstructured[all-docs]) (44.0.0)\n",
      "Requirement already satisfied: Deprecated in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pikepdf->unstructured[all-docs]) (1.2.18)\n",
      "Requirement already satisfied: olefile in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from python-oxmsg->unstructured[all-docs]) (0.47)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests->unstructured[all-docs]) (3.10)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests->unstructured[all-docs]) (2.3.0)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests->unstructured[all-docs]) (2024.12.14)\n",
      "Requirement already satisfied: aiofiles>=24.1.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-client->unstructured[all-docs]) (24.1.0)\n",
      "Requirement already satisfied: eval-type-backport>=0.2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-client->unstructured[all-docs]) (0.2.2)\n",
      "Requirement already satisfied: httpx>=0.27.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-client->unstructured[all-docs]) (0.28.1)\n",
      "Requirement already satisfied: nest-asyncio>=1.6.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-client->unstructured[all-docs]) (1.6.0)\n",
      "Requirement already satisfied: pydantic>=2.10.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-client->unstructured[all-docs]) (2.10.4)\n",
      "Requirement already satisfied: requests-toolbelt>=1.0.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-client->unstructured[all-docs]) (1.0.0)\n",
      "Requirement already satisfied: typing-inspection>=0.4.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from unstructured-client->unstructured[all-docs]) (0.4.0)\n",
      "Requirement already satisfied: cffi>=1.12 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from cryptography>=36.0.0->pdfminer.six->unstructured[all-docs]) (1.17.1)\n",
      "Requirement already satisfied: googleapis-common-protos<2.0.0,>=1.56.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-api-core!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.1->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.1->google-cloud-vision->unstructured[all-docs]) (1.66.0)\n",
      "Requirement already satisfied: grpcio<2.0dev,>=1.33.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.1->google-cloud-vision->unstructured[all-docs]) (1.71.0)\n",
      "Requirement already satisfied: grpcio-status<2.0.dev0,>=1.33.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0dev,>=1.34.1->google-cloud-vision->unstructured[all-docs]) (1.71.0)\n",
      "Requirement already satisfied: cachetools<6.0,>=2.0.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-auth!=2.24.0,!=2.25.0,<3.0.0dev,>=2.14.1->google-cloud-vision->unstructured[all-docs]) (5.5.1)\n",
      "Requirement already satisfied: pyasn1-modules>=0.2.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-auth!=2.24.0,!=2.25.0,<3.0.0dev,>=2.14.1->google-cloud-vision->unstructured[all-docs]) (0.4.1)\n",
      "Requirement already satisfied: rsa<5,>=3.1.4 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-auth!=2.24.0,!=2.25.0,<3.0.0dev,>=2.14.1->google-cloud-vision->unstructured[all-docs]) (4.9)\n",
      "Requirement already satisfied: anyio in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from httpx>=0.27.0->unstructured-client->unstructured[all-docs]) (4.8.0)\n",
      "Requirement already satisfied: httpcore==1.* in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from httpx>=0.27.0->unstructured-client->unstructured[all-docs]) (1.0.7)\n",
      "Requirement already satisfied: h11<0.15,>=0.13 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from httpcore==1.*->httpx>=0.27.0->unstructured-client->unstructured[all-docs]) (0.14.0)\n",
      "Requirement already satisfied: antlr4-python3-runtime==4.9.* in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from omegaconf>=2.0->effdet->unstructured[all-docs]) (4.9.3)\n",
      "Requirement already satisfied: PyYAML>=5.1.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from omegaconf>=2.0->effdet->unstructured[all-docs]) (6.0.2)\n",
      "Requirement already satisfied: contourpy>=1.0.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib->unstructured-inference>=0.8.10->unstructured[all-docs]) (1.3.1)\n",
      "Requirement already satisfied: cycler>=0.10 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib->unstructured-inference>=0.8.10->unstructured[all-docs]) (0.12.1)\n",
      "Requirement already satisfied: fonttools>=4.22.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib->unstructured-inference>=0.8.10->unstructured[all-docs]) (4.56.0)\n",
      "Requirement already satisfied: kiwisolver>=1.3.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib->unstructured-inference>=0.8.10->unstructured[all-docs]) (1.4.8)\n",
      "Requirement already satisfied: pyparsing>=2.3.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib->unstructured-inference>=0.8.10->unstructured[all-docs]) (3.2.1)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pydantic>=2.10.3->unstructured-client->unstructured[all-docs]) (0.7.0)\n",
      "Requirement already satisfied: pydantic-core==2.27.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pydantic>=2.10.3->unstructured-client->unstructured[all-docs]) (2.27.2)\n",
      "Requirement already satisfied: safetensors in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from timm->unstructured-inference>=0.8.10->unstructured[all-docs]) (0.5.2)\n",
      "Requirement already satisfied: filelock in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch->unstructured-inference>=0.8.10->unstructured[all-docs]) (3.17.0)\n",
      "Requirement already satisfied: jinja2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch->unstructured-inference>=0.8.10->unstructured[all-docs]) (3.1.5)\n",
      "Requirement already satisfied: fsspec in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch->unstructured-inference>=0.8.10->unstructured[all-docs]) (2024.9.0)\n",
      "Requirement already satisfied: setuptools in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch->unstructured-inference>=0.8.10->unstructured[all-docs]) (75.8.0)\n",
      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from sympy->onnxruntime>=1.19.0->unstructured[all-docs]) (1.3.0)\n",
      "Requirement already satisfied: tokenizers<0.22,>=0.21 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from transformers>=4.25.1->unstructured-inference>=0.8.10->unstructured[all-docs]) (0.21.0)\n",
      "Requirement already satisfied: mypy-extensions>=0.3.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from typing-inspect<1,>=0.4.0->dataclasses-json->unstructured[all-docs]) (1.0.0)\n",
      "Requirement already satisfied: humanfriendly>=9.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from coloredlogs->onnxruntime>=1.19.0->unstructured[all-docs]) (10.0)\n",
      "Requirement already satisfied: pycparser in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from cffi>=1.12->cryptography>=36.0.0->pdfminer.six->unstructured[all-docs]) (2.22)\n",
      "Requirement already satisfied: pyasn1<0.7.0,>=0.4.6 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pyasn1-modules>=0.2.1->google-auth!=2.24.0,!=2.25.0,<3.0.0dev,>=2.14.1->google-cloud-vision->unstructured[all-docs]) (0.6.1)\n",
      "Requirement already satisfied: sniffio>=1.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from anyio->httpx>=0.27.0->unstructured-client->unstructured[all-docs]) (1.3.1)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from jinja2->torch->unstructured-inference>=0.8.10->unstructured[all-docs]) (3.0.2)\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "pip install \"unstructured[all-docs]\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "15e44792",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: langchain in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (0.3.24)\n",
      "Requirement already satisfied: openai in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (1.76.0)\n",
      "Requirement already satisfied: langchain-chroma in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (0.2.3)\n",
      "Requirement already satisfied: langchain-experimental in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (0.3.4)\n",
      "Requirement already satisfied: langchain-core<1.0.0,>=0.3.55 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain) (0.3.55)\n",
      "Requirement already satisfied: langchain-text-splitters<1.0.0,>=0.3.8 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain) (0.3.8)\n",
      "Requirement already satisfied: langsmith<0.4,>=0.1.17 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain) (0.3.2)\n",
      "Requirement already satisfied: pydantic<3.0.0,>=2.7.4 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain) (2.10.4)\n",
      "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain) (2.0.37)\n",
      "Requirement already satisfied: requests<3,>=2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain) (2.32.3)\n",
      "Requirement already satisfied: PyYAML>=5.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain) (6.0.2)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from openai) (4.8.0)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from openai) (1.9.0)\n",
      "Requirement already satisfied: httpx<1,>=0.23.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from openai) (0.28.1)\n",
      "Requirement already satisfied: jiter<1,>=0.4.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from openai) (0.8.2)\n",
      "Requirement already satisfied: sniffio in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from openai) (1.3.1)\n",
      "Requirement already satisfied: tqdm>4 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from openai) (4.67.1)\n",
      "Requirement already satisfied: typing-extensions<5,>=4.11 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from openai) (4.12.2)\n",
      "Requirement already satisfied: numpy>=1.26.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-chroma) (1.26.4)\n",
      "Requirement already satisfied: chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-chroma) (0.6.3)\n",
      "Requirement already satisfied: langchain-community<0.4.0,>=0.3.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-experimental) (0.3.19)\n",
      "Requirement already satisfied: idna>=2.8 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from anyio<5,>=3.5.0->openai) (3.10)\n",
      "Requirement already satisfied: build>=1.0.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.2.2.post1)\n",
      "Requirement already satisfied: chroma-hnswlib==0.7.6 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.7.6)\n",
      "Requirement already satisfied: fastapi>=0.95.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.115.6)\n",
      "Requirement already satisfied: uvicorn>=0.18.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from uvicorn[standard]>=0.18.3->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.34.0)\n",
      "Requirement already satisfied: posthog>=2.4.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (3.11.0)\n",
      "Requirement already satisfied: onnxruntime>=1.14.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.19.2)\n",
      "Requirement already satisfied: opentelemetry-api>=1.2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.29.0)\n",
      "Requirement already satisfied: opentelemetry-exporter-otlp-proto-grpc>=1.2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.29.0)\n",
      "Requirement already satisfied: opentelemetry-instrumentation-fastapi>=0.41b0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.50b0)\n",
      "Requirement already satisfied: opentelemetry-sdk>=1.2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.29.0)\n",
      "Requirement already satisfied: tokenizers>=0.13.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.21.0)\n",
      "Requirement already satisfied: pypika>=0.48.9 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.48.9)\n",
      "Requirement already satisfied: overrides>=7.3.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (7.7.0)\n",
      "Requirement already satisfied: importlib-resources in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (6.5.2)\n",
      "Requirement already satisfied: grpcio>=1.58.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.71.0)\n",
      "Requirement already satisfied: bcrypt>=4.0.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (4.2.1)\n",
      "Requirement already satisfied: typer>=0.9.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.15.1)\n",
      "Requirement already satisfied: kubernetes>=28.1.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (32.0.0)\n",
      "Requirement already satisfied: tenacity>=8.2.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (8.5.0)\n",
      "Requirement already satisfied: mmh3>=4.0.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (5.1.0)\n",
      "Requirement already satisfied: orjson>=3.9.12 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (3.10.15)\n",
      "Requirement already satisfied: rich>=10.11.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (13.9.4)\n",
      "Requirement already satisfied: certifi in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from httpx<1,>=0.23.0->openai) (2024.12.14)\n",
      "Requirement already satisfied: httpcore==1.* in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from httpx<1,>=0.23.0->openai) (1.0.7)\n",
      "Requirement already satisfied: h11<0.15,>=0.13 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.14.0)\n",
      "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-community<0.4.0,>=0.3.0->langchain-experimental) (3.11.11)\n",
      "Requirement already satisfied: dataclasses-json<0.7,>=0.5.7 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-community<0.4.0,>=0.3.0->langchain-experimental) (0.6.7)\n",
      "Requirement already satisfied: pydantic-settings<3.0.0,>=2.4.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-community<0.4.0,>=0.3.0->langchain-experimental) (2.7.1)\n",
      "Requirement already satisfied: httpx-sse<1.0.0,>=0.4.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-community<0.4.0,>=0.3.0->langchain-experimental) (0.4.0)\n",
      "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-core<1.0.0,>=0.3.55->langchain) (1.33)\n",
      "Requirement already satisfied: packaging<25,>=23.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langchain-core<1.0.0,>=0.3.55->langchain) (24.2)\n",
      "Requirement already satisfied: requests-toolbelt<2.0.0,>=1.0.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langsmith<0.4,>=0.1.17->langchain) (1.0.0)\n",
      "Requirement already satisfied: zstandard<0.24.0,>=0.23.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from langsmith<0.4,>=0.1.17->langchain) (0.23.0)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pydantic<3.0.0,>=2.7.4->langchain) (0.7.0)\n",
      "Requirement already satisfied: pydantic-core==2.27.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pydantic<3.0.0,>=2.7.4->langchain) (2.27.2)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests<3,>=2->langchain) (3.4.1)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests<3,>=2->langchain) (2.3.0)\n",
      "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (2.4.4)\n",
      "Requirement already satisfied: aiosignal>=1.1.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (1.3.2)\n",
      "Requirement already satisfied: attrs>=17.3.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (25.1.0)\n",
      "Requirement already satisfied: frozenlist>=1.1.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (1.5.0)\n",
      "Requirement already satisfied: multidict<7.0,>=4.5 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (6.1.0)\n",
      "Requirement already satisfied: propcache>=0.2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (0.2.1)\n",
      "Requirement already satisfied: yarl<2.0,>=1.17.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (1.18.3)\n",
      "Requirement already satisfied: pyproject_hooks in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from build>=1.0.3->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.2.0)\n",
      "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from dataclasses-json<0.7,>=0.5.7->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (3.26.0)\n",
      "Requirement already satisfied: typing-inspect<1,>=0.4.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from dataclasses-json<0.7,>=0.5.7->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (0.9.0)\n",
      "Requirement already satisfied: starlette<0.42.0,>=0.40.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from fastapi>=0.95.2->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.41.3)\n",
      "Requirement already satisfied: jsonpointer>=1.9 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from jsonpatch<2.0,>=1.33->langchain-core<1.0.0,>=0.3.55->langchain) (3.0.0)\n",
      "Requirement already satisfied: six>=1.9.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.17.0)\n",
      "Requirement already satisfied: python-dateutil>=2.5.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (2.9.0.post0)\n",
      "Requirement already satisfied: google-auth>=1.0.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (2.38.0)\n",
      "Requirement already satisfied: websocket-client!=0.40.0,!=0.41.*,!=0.42.*,>=0.32.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.8.0)\n",
      "Requirement already satisfied: requests-oauthlib in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (2.0.0)\n",
      "Requirement already satisfied: oauthlib>=3.2.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (3.2.2)\n",
      "Requirement already satisfied: durationpy>=0.7 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.9)\n",
      "Requirement already satisfied: coloredlogs in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnxruntime>=1.14.1->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (15.0.1)\n",
      "Requirement already satisfied: flatbuffers in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnxruntime>=1.14.1->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (25.1.24)\n",
      "Requirement already satisfied: protobuf in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnxruntime>=1.14.1->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (5.29.3)\n",
      "Requirement already satisfied: sympy in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from onnxruntime>=1.14.1->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.13.1)\n",
      "Requirement already satisfied: deprecated>=1.2.6 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-api>=1.2.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.2.18)\n",
      "Requirement already satisfied: importlib-metadata<=8.5.0,>=6.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-api>=1.2.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (8.5.0)\n",
      "Requirement already satisfied: googleapis-common-protos~=1.52 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.66.0)\n",
      "Requirement already satisfied: opentelemetry-exporter-otlp-proto-common==1.29.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.29.0)\n",
      "Requirement already satisfied: opentelemetry-proto==1.29.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.29.0)\n",
      "Requirement already satisfied: opentelemetry-instrumentation-asgi==0.50b0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.50b0)\n",
      "Requirement already satisfied: opentelemetry-instrumentation==0.50b0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.50b0)\n",
      "Requirement already satisfied: opentelemetry-semantic-conventions==0.50b0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.50b0)\n",
      "Requirement already satisfied: opentelemetry-util-http==0.50b0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.50b0)\n",
      "Requirement already satisfied: wrapt<2.0.0,>=1.0.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-instrumentation==0.50b0->opentelemetry-instrumentation-fastapi>=0.41b0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.17.2)\n",
      "Requirement already satisfied: asgiref~=3.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from opentelemetry-instrumentation-asgi==0.50b0->opentelemetry-instrumentation-fastapi>=0.41b0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (3.8.1)\n",
      "Requirement already satisfied: monotonic>=1.5 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from posthog>=2.4.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.6)\n",
      "Requirement already satisfied: backoff>=1.10.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from posthog>=2.4.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (2.2.1)\n",
      "Requirement already satisfied: python-dotenv>=0.21.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pydantic-settings<3.0.0,>=2.4.0->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (1.0.1)\n",
      "Requirement already satisfied: markdown-it-py>=2.2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from rich>=10.11.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (3.0.0)\n",
      "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from rich>=10.11.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (2.19.1)\n",
      "Requirement already satisfied: huggingface-hub<1.0,>=0.16.4 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from tokenizers>=0.13.2->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.30.1)\n",
      "Requirement already satisfied: click>=8.0.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from typer>=0.9.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (8.1.8)\n",
      "Requirement already satisfied: shellingham>=1.3.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from typer>=0.9.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.5.4)\n",
      "Requirement already satisfied: httptools>=0.6.3 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from uvicorn[standard]>=0.18.3->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.6.4)\n",
      "Requirement already satisfied: uvloop!=0.15.0,!=0.15.1,>=0.14.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from uvicorn[standard]>=0.18.3->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.21.0)\n",
      "Requirement already satisfied: watchfiles>=0.13 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from uvicorn[standard]>=0.18.3->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.0.4)\n",
      "Requirement already satisfied: websockets>=10.4 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from uvicorn[standard]>=0.18.3->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (14.2)\n",
      "Requirement already satisfied: cachetools<6.0,>=2.0.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (5.5.1)\n",
      "Requirement already satisfied: pyasn1-modules>=0.2.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.4.1)\n",
      "Requirement already satisfied: rsa<5,>=3.1.4 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (4.9)\n",
      "Requirement already satisfied: filelock in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers>=0.13.2->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (3.17.0)\n",
      "Requirement already satisfied: fsspec>=2023.5.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers>=0.13.2->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (2024.9.0)\n",
      "Requirement already satisfied: zipp>=3.20 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from importlib-metadata<=8.5.0,>=6.0->opentelemetry-api>=1.2.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (3.21.0)\n",
      "Requirement already satisfied: mdurl~=0.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from markdown-it-py>=2.2.0->rich>=10.11.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.1.2)\n",
      "Requirement already satisfied: mypy-extensions>=0.3.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7,>=0.5.7->langchain-community<0.4.0,>=0.3.0->langchain-experimental) (1.0.0)\n",
      "Requirement already satisfied: humanfriendly>=9.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from coloredlogs->onnxruntime>=1.14.1->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (10.0)\n",
      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from sympy->onnxruntime>=1.14.1->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (1.3.0)\n",
      "Requirement already satisfied: pyasn1<0.7.0,>=0.4.6 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pyasn1-modules>=0.2.1->google-auth>=1.0.1->kubernetes>=28.1.0->chromadb!=0.5.10,!=0.5.11,!=0.5.12,!=0.5.4,!=0.5.5,!=0.5.7,!=0.5.9,<0.7.0,>=0.4.0->langchain-chroma) (0.6.1)\n"
     ]
    }
   ],
   "source": [
    "! pip install -U langchain openai langchain-chroma langchain-experimental"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "33ead849",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: pillow in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (11.1.0)\n",
      "Requirement already satisfied: pydantic in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (2.10.4)\n",
      "Requirement already satisfied: lxml in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (5.3.1)\n",
      "Requirement already satisfied: matplotlib in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (3.10.1)\n",
      "Requirement already satisfied: tiktoken in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (0.8.0)\n",
      "Requirement already satisfied: open_clip_torch in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (2.31.0)\n",
      "Requirement already satisfied: torch in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (2.6.0)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pydantic) (0.7.0)\n",
      "Requirement already satisfied: pydantic-core==2.27.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pydantic) (2.27.2)\n",
      "Requirement already satisfied: typing-extensions>=4.12.2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from pydantic) (4.12.2)\n",
      "Requirement already satisfied: contourpy>=1.0.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib) (1.3.1)\n",
      "Requirement already satisfied: cycler>=0.10 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib) (0.12.1)\n",
      "Requirement already satisfied: fonttools>=4.22.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib) (4.56.0)\n",
      "Requirement already satisfied: kiwisolver>=1.3.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib) (1.4.8)\n",
      "Requirement already satisfied: numpy>=1.23 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib) (1.26.4)\n",
      "Requirement already satisfied: packaging>=20.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib) (24.2)\n",
      "Requirement already satisfied: pyparsing>=2.3.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib) (3.2.1)\n",
      "Requirement already satisfied: python-dateutil>=2.7 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from matplotlib) (2.9.0.post0)\n",
      "Requirement already satisfied: regex>=2022.1.18 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from tiktoken) (2024.11.6)\n",
      "Requirement already satisfied: requests>=2.26.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from tiktoken) (2.32.3)\n",
      "Requirement already satisfied: torchvision in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from open_clip_torch) (0.21.0)\n",
      "Requirement already satisfied: ftfy in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from open_clip_torch) (6.3.1)\n",
      "Requirement already satisfied: tqdm in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from open_clip_torch) (4.67.1)\n",
      "Requirement already satisfied: huggingface-hub in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from open_clip_torch) (0.30.1)\n",
      "Requirement already satisfied: safetensors in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from open_clip_torch) (0.5.2)\n",
      "Requirement already satisfied: timm in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from open_clip_torch) (1.0.12)\n",
      "Requirement already satisfied: filelock in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch) (3.17.0)\n",
      "Requirement already satisfied: networkx in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch) (3.3)\n",
      "Requirement already satisfied: jinja2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch) (3.1.5)\n",
      "Requirement already satisfied: fsspec in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch) (2024.9.0)\n",
      "Requirement already satisfied: setuptools in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch) (75.8.0)\n",
      "Requirement already satisfied: sympy==1.13.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from torch) (1.13.1)\n",
      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from sympy==1.13.1->torch) (1.3.0)\n",
      "Requirement already satisfied: six>=1.5 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from python-dateutil>=2.7->matplotlib) (1.17.0)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests>=2.26.0->tiktoken) (3.4.1)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests>=2.26.0->tiktoken) (3.10)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests>=2.26.0->tiktoken) (2.3.0)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from requests>=2.26.0->tiktoken) (2024.12.14)\n",
      "Requirement already satisfied: wcwidth in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from ftfy->open_clip_torch) (0.2.13)\n",
      "Requirement already satisfied: pyyaml>=5.1 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from huggingface-hub->open_clip_torch) (6.0.2)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages (from jinja2->torch) (3.0.2)\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "pip install pillow pydantic lxml pillow matplotlib tiktoken open_clip_torch torch"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "f811fc0d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os \n",
    "from unstructured.partition.pdf import partition_pdf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "481d5264",
   "metadata": {},
   "outputs": [],
   "source": [
    "path = \"/Users/rafsanmallik/Desktop/lab/kh\"\n",
    "pdf_path = os.path.join(path, \"/Users/rafsanmallik/Desktop/lab/kh/Entacid.pdf\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "5740c5e9",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "raw_pdf_elements = partition_pdf(\n",
    "    filename=pdf_path,\n",
    "    extract_images_in_pdf=True,\n",
    "    infer_table_structure=True,\n",
    "    chunking_strategy=\"by_title\",\n",
    "    max_characters=4000,\n",
    "    new_after_n_chars=3000,\n",
    "    combine_text_under_n_chars=2000,\n",
    "    image_output_dir_path=path,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "144faa1c",
   "metadata": {},
   "outputs": [],
   "source": [
    "tables = []\n",
    "texts = []\n",
    "for element in raw_pdf_elements:\n",
    "    if \"unstructured.documents.elements.Table\" in str(type(element)):\n",
    "        tables.append(str(element))\n",
    "    elif \"unstructured.documents.elements.CompositeElement\" in str(type(element)):\n",
    "        texts.append(str(element))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "9a4cbd1c",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.embeddings import FakeEmbeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "9f172717",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['af106fab-985a-4912-afe9-9b93a7197d71',\n",
       " '95eaf5db-0958-4b31-b586-f3f430a23ef5',\n",
       " 'a156b82e-e952-4c2f-83bb-f6992f886f39',\n",
       " '52faae4d-f7c3-431b-9671-78a3cf85a9e9',\n",
       " '9131d4ba-01eb-4669-baea-9ee744520b51',\n",
       " 'b0525f95-477b-4029-a8b5-2b39f50e65ca',\n",
       " 'aeacb6df-ec40-4cf2-8dc4-3ad28eb2e01b',\n",
       " '7b107971-6185-4e72-8b5d-ce5d5d4e9ee8',\n",
       " '62d4e49c-4d27-4ca3-9b2c-d72ec08da255',\n",
       " 'eb5985e7-4148-4016-9c86-88fdd246586c',\n",
       " '9c2366bd-575d-4442-b984-38b42e3e2f63',\n",
       " '64f91ac4-1ef1-487c-98de-e701c2b0fdbe',\n",
       " '38b52da7-258f-4a7a-8404-0dd73d75ca82',\n",
       " 'c90f5bbd-e808-42e7-aad8-97aad8f7fae4',\n",
       " '4e8f3c40-8e17-46e1-a098-94de2c35f585',\n",
       " '365232b6-2001-49f4-83c6-1aa2095f44df',\n",
       " '6015fbe3-85c1-4e27-98f9-fea120aefd02',\n",
       " 'abf4a5a7-87f9-4045-aeac-23aa4889f517',\n",
       " '6840aa5e-fc9f-4dd9-ace2-4e44f56dc39b',\n",
       " '678e36e0-61ca-4cc9-9e9b-c9755c9c0983',\n",
       " '12a99306-17b3-4aeb-adf6-77d1e6e2104f',\n",
       " 'fd781465-8cc9-4675-8e56-9cd74cc8b3ec',\n",
       " 'd2912a16-d809-4d3e-b404-aee346e7b108',\n",
       " '22dd0dda-04c5-4ae4-8892-26edddaedaa9',\n",
       " 'ea7a125a-beec-4103-aa00-25f18fe3d3af',\n",
       " '20c1b52f-cac7-4db0-b4c9-a0bd8f6dc38a',\n",
       " '4f343e9c-3833-4ca0-81c7-cb501b173863',\n",
       " '32b4e2be-4646-49ab-a54b-097097af6e7b',\n",
       " 'ad016d51-5dfd-4b7c-b222-5f92d9b9b5ce',\n",
       " '9be55cf7-f745-40c4-b084-27d78433836e',\n",
       " '6d92c4e7-50f5-46e8-b226-064f8c3200f1',\n",
       " '9dfc101e-c455-4d3d-bda4-fa53e61e7b2e',\n",
       " '65788db6-2983-4743-9b1a-ff807b09299e',\n",
       " '7cfb25bb-c0d5-40cc-b788-d69de5eb691b',\n",
       " '2326c217-21b8-4009-b56d-202184343e94',\n",
       " '7afc8320-583f-42ce-b80f-e52e9a8dee5e',\n",
       " '90bd879e-9df0-48f6-aac3-049be176578d']"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import os\n",
    "import uuid\n",
    "\n",
    "import chromadb\n",
    "import numpy as np\n",
    "from langchain_chroma import Chroma\n",
    "from langchain_experimental.open_clip import OpenCLIPEmbeddings\n",
    "from PIL import Image as _PILImage\n",
    "\n",
    "# Create chroma\n",
    "vectorstore = Chroma(\n",
    "    collection_name=\"mm_rag_clip_photos\", embedding_function=OpenCLIPEmbeddings()\n",
    ")\n",
    "\n",
    "# Get image URIs with .jpg extension only\n",
    "image_uris = sorted(\n",
    "    [\n",
    "        os.path.join(path, image_name)\n",
    "        for image_name in os.listdir(path)\n",
    "        if image_name.endswith(\".jpg\")\n",
    "    ]\n",
    ")\n",
    "\n",
    "# Add images\n",
    "vectorstore.add_images(uris=image_uris)\n",
    "\n",
    "# Add documents\n",
    "vectorstore.add_texts(texts=texts)\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "2f6dc50e",
   "metadata": {},
   "outputs": [],
   "source": [
    "retriever = vectorstore.as_retriever(\n",
    "    search_type=\"similarity_score_threshold\",\n",
    "    search_kwargs={\n",
    "        \"score_threshold\":0.05,  # Tweak this value\n",
    "        \"k\": 50\n",
    "    }\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "651590c0",
   "metadata": {},
   "outputs": [],
   "source": [
    "import base64\n",
    "import io\n",
    "from io import BytesIO\n",
    "\n",
    "import numpy as np\n",
    "from PIL import Image\n",
    "\n",
    "\n",
    "def resize_base64_image(base64_string, size=(128, 128)):\n",
    "    \"\"\"\n",
    "    Resize an image encoded as a Base64 string.\n",
    "\n",
    "    Args:\n",
    "    base64_string (str): Base64 string of the original image.\n",
    "    size (tuple): Desired size of the image as (width, height).\n",
    "\n",
    "    Returns:\n",
    "    str: Base64 string of the resized image.\n",
    "    \"\"\"\n",
    "    # Decode the Base64 string\n",
    "    img_data = base64.b64decode(base64_string)\n",
    "    img = Image.open(io.BytesIO(img_data))\n",
    "\n",
    "    # Resize the image\n",
    "    resized_img = img.resize(size, Image.LANCZOS)\n",
    "\n",
    "    # Save the resized image to a bytes buffer\n",
    "    buffered = io.BytesIO()\n",
    "    resized_img.save(buffered, format=img.format)\n",
    "\n",
    "    # Encode the resized image to Base64\n",
    "    return base64.b64encode(buffered.getvalue()).decode(\"utf-8\")\n",
    "\n",
    "\n",
    "def is_base64(s):\n",
    "    \"\"\"Check if a string is Base64 encoded\"\"\"\n",
    "    try:\n",
    "        return base64.b64encode(base64.b64decode(s)) == s.encode()\n",
    "    except Exception:\n",
    "        return False\n",
    "\n",
    "\n",
    "def split_image_text_types(docs):\n",
    "    \"\"\"Split numpy array images and texts\"\"\"\n",
    "    images = []\n",
    "    text = []\n",
    "    for doc in docs:\n",
    "        doc = doc.page_content  # Extract Document contents\n",
    "        if is_base64(doc):\n",
    "            # Resize image to avoid OAI server error\n",
    "            images.append(\n",
    "                resize_base64_image(doc, size=(250, 250))\n",
    "            )  # base64 encoded str\n",
    "        else:\n",
    "            text.append(doc)\n",
    "    return {\"images\": images, \"texts\": text}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "15bc3a9e",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_ollama import OllamaLLM\n",
    "from langchain_core.messages import HumanMessage\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain_core.runnables import RunnableLambda, RunnablePassthrough\n",
    "\n",
    "def prompt_func(data_dict):\n",
    "    formatted_texts = \"\\n\".join(data_dict[\"context\"][\"texts\"])\n",
    "    messages = []\n",
    "\n",
    "  \n",
    "    if data_dict[\"context\"][\"images\"]:\n",
    "        image_message = {\n",
    "            \"type\": \"image_url\",\n",
    "            \"image_url\": {\n",
    "                \"url\": f\"data:image/jpeg;base64,{data_dict['context']['images'][0]}\"\n",
    "            },\n",
    "        }\n",
    "        messages.append(image_message)\n",
    "\n",
    "\n",
    "    text_message = {\n",
    "        \"type\": \"text\",\n",
    "        \"text\": (\n",
    "            \"As an expert pharmacist, your task is to analyze and interpret images of medicines and prescriptions and suggest medicines and help patients and doctors when they ask you questions ...\\n\\n\"\n",
    "            f\"User-provided keywords: {data_dict['question']}\\n\\n\"\n",
    "            \"Text and / or tables:\\n\"\n",
    "            f\"{formatted_texts}\"\n",
    "        ),\n",
    "    }\n",
    "    messages.append(text_message)\n",
    "\n",
    "    return [HumanMessage(content=messages)]\n",
    "\n",
    "\n",
    "model = OllamaLLM(model=\"gemma3:4b\", temperature=0.1, max_tokens=2000)  \n",
    "\n",
    "\n",
    "chain = (\n",
    "    {\n",
    "        \"context\": retriever | RunnableLambda(split_image_text_types),\n",
    "        \"question\": RunnablePassthrough(),\n",
    "    }\n",
    "    | RunnableLambda(prompt_func)\n",
    "    | model\n",
    "    | StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "3e889b81",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/site-packages/langchain_core/vectorstores/base.py:1082: UserWarning: Relevance scores must be between 0 and 1, got [(Document(id='deb1500c-c3c2-4882-b65f-f5d8b6f7766d', metadata={}, page_content=\"milk. Exercise caution when administering to a nursing mother. Precautions & Warnings For external use only. Keep away from eyes, nose, mouth and other mucous membrane. Use of antibiotics (especially prolonged or repeated therapy) may result in bacterial or fungal overgrowth of non-susceptible organisms. Such overgrowth may lead to a secondary infection. Take appropriate measures if superinfections occur. Use in Special Populations Safety and effectiveness in children less than 12 years have not been established. Therapeutic Class Topical antibiotics for Acne Storage Conditions Keep below 25C temperature, away from light & moisture. Keep out of the reach of children. Pack Image: Eromycin 3% Lotion\\n\\nAcorex Syrup Pack Image Ambroxol Hydrochloride 15 mg/5 ml Apex Pharmaceuticals Ltd. 100\\n\\nml bottle:  46.00 Alternate Brands Innovator's Monograph   Indications Acorex is\\n\\nindicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day Syrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Acorex should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Acorex might not be expectorated. Contraindications Contraindicated in known hypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Acorex should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not\"), 0.0748238230378434), (Document(id='9dfc101e-c455-4d3d-bda4-fa53e61e7b2e', metadata={}, page_content=\"milk. Exercise caution when administering to a nursing mother. Precautions & Warnings For external use only. Keep away from eyes, nose, mouth and other mucous membrane. Use of antibiotics (especially prolonged or repeated therapy) may result in bacterial or fungal overgrowth of non-susceptible organisms. Such overgrowth may lead to a secondary infection. Take appropriate measures if superinfections occur. Use in Special Populations Safety and effectiveness in children less than 12 years have not been established. Therapeutic Class Topical antibiotics for Acne Storage Conditions Keep below 25C temperature, away from light & moisture. Keep out of the reach of children. Pack Image: Eromycin 3% Lotion\\n\\nAcorex Syrup Pack Image Ambroxol Hydrochloride 15 mg/5 ml Apex Pharmaceuticals Ltd. 100\\n\\nml bottle:  46.00 Alternate Brands Innovator's Monograph   Indications Acorex is\\n\\nindicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day Syrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Acorex should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Acorex might not be expectorated. Contraindications Contraindicated in known hypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Acorex should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not\"), 0.0748238230378434), (Document(id='950b71ff-7586-4df5-ab1e-f7c94346cd91', metadata={}, page_content=\"Syrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.\\n\\ntimes a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Ambokof should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambokof might not be expectorated. Contraindications Contraindicated in known\\n\\nhypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Ambokof should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30C, Keep out of the reach of children.\\n\\nAmbolin Pediatric Drops Ambroxol Hydrochloride 6 mg/ml Virgo Pharmaceuticals Ltd. 15 ml bottle:  25.00 Also available as: 15 mg/5 ml (Syrup) Alternate Brands Innovator's Monograph   Indications Ambolin is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It impro\"), 0.03697182268390653), (Document(id='90bd879e-9df0-48f6-aac3-049be176578d', metadata={}, page_content=\"Syrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.\\n\\ntimes a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Ambokof should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambokof might not be expectorated. Contraindications Contraindicated in known\\n\\nhypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Ambokof should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30C, Keep out of the reach of children.\\n\\nAmbolin Pediatric Drops Ambroxol Hydrochloride 6 mg/ml Virgo Pharmaceuticals Ltd. 15 ml bottle:  25.00 Also available as: 15 mg/5 ml (Syrup) Alternate Brands Innovator's Monograph   Indications Ambolin is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It impro\"), 0.03697182268390653), (Document(id='8d54d9e3-bbde-4ee7-b6e0-b7d3c74905e2', metadata={}, page_content=\"daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day Syrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Ambix should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambix might not be expectorated. Contraindications Contraindicated in known hypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Ambix should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30C, Keep out of the reach of children.\\n\\nAmbokof Syrup Ambroxol Hydrochloride 15 mg/5 ml Novelta Bestway Pharma Ltd. 100 ml bottle:  40.00 Also available as: 6 mg/ml (Drops) Alternate Brands Innovator's Monograph   Indications Ambokof is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day\"), 0.03381578237371374), (Document(id='7afc8320-583f-42ce-b80f-e52e9a8dee5e', metadata={}, page_content=\"daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day Syrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Ambix should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambix might not be expectorated. Contraindications Contraindicated in known hypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Ambix should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30C, Keep out of the reach of children.\\n\\nAmbokof Syrup Ambroxol Hydrochloride 15 mg/5 ml Novelta Bestway Pharma Ltd. 100 ml bottle:  40.00 Also available as: 6 mg/ml (Drops) Alternate Brands Innovator's Monograph   Indications Ambokof is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day\"), 0.03381578237371374), (Document(id='48cae6b1-ed6e-45f3-9869-7993cd766443', metadata={}, page_content=\"times a day\\n\\nSyrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.\\n\\nSustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Ambeet should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambeet might not be expectorated. Contraindications Contraindicated in known hypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Ambeet should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30C, Keep out of the reach of children.\\n\\nAmbeet Capsule (Sustained Release) Ambroxol Hydrochloride 75 mg Ethical Drugs Limited Unit Price:  5.00 (5 x 6:  150.00) Strip Price:  30.00 Also available as: 15 mg/5 ml (Syrup) Alternate Brands Innovator's Monograph   Indications Ambeet is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic\\n\\npneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12\"), 0.011928249592430329), (Document(id='7cfb25bb-c0d5-40cc-b788-d69de5eb691b', metadata={}, page_content=\"times a day\\n\\nSyrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.\\n\\nSustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Ambeet should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambeet might not be expectorated. Contraindications Contraindicated in known hypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Ambeet should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30C, Keep out of the reach of children.\\n\\nAmbeet Capsule (Sustained Release) Ambroxol Hydrochloride 75 mg Ethical Drugs Limited Unit Price:  5.00 (5 x 6:  150.00) Strip Price:  30.00 Also available as: 15 mg/5 ml (Syrup) Alternate Brands Innovator's Monograph   Indications Ambeet is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic\\n\\npneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12\"), 0.011928249592430329), (Document(id='410a7cf9-1149-48be-870e-111d19f025cf', metadata={}, page_content='insomnia, anxiety, agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, gait\\n\\nabnormality, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucinations,\\n\\npsychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients\\n\\nwith prior history of seizure disorders. Hyperthermia has also been observed.There is no\\n\\nspecific antidote for an overdose of Amantril. However, slowly administered intravenous\\n\\nphysostigmine in 1 and 2 mg doses in an adult at 1- to 2-hour intervals and 0.5 mg doses in a\\n\\nchild at 5- to 10-minute intervals up to a maximum of 2 mg/hour have been reported to be effective in the control of central nervous system toxicity caused by Amantril. For acute overdosing, general supportive measures should be employed along with immediate gastric lavage or induction of emesis. Fluids should be forced, and if necessary, given intravenously. The pH of the urine has been reported to influence the excretion rate of Amantril. Since the excretion rate of Amantril increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. The blood pressure, pulse, respiration and temperature should be monitored. The patient should be observed for hyperactivity and convulsions; if required, sedation, and anticonvulsant therapy should be administered. The patient should be observed for the possible development of arrhythmias and hypotension; if required, appropriate antiarrhythmic and antihypotensive therapy should be given. Electrocardiographic monitoring may be required after ingestion, since malignant tachyarrhythmias can appear after overdose. Therapeutic Class Respiratory viral infections (Influenza) Storage Conditions Keep away from the reach of children. Store in a cool & dry place. Protect from light. Pack Image: Amantril 100 mg Capsule'), -0.009679343821043851), (Document(id='fd781465-8cc9-4675-8e56-9cd74cc8b3ec', metadata={}, page_content='insomnia, anxiety, agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, gait\\n\\nabnormality, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucinations,\\n\\npsychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients\\n\\nwith prior history of seizure disorders. Hyperthermia has also been observed.There is no\\n\\nspecific antidote for an overdose of Amantril. However, slowly administered intravenous\\n\\nphysostigmine in 1 and 2 mg doses in an adult at 1- to 2-hour intervals and 0.5 mg doses in a\\n\\nchild at 5- to 10-minute intervals up to a maximum of 2 mg/hour have been reported to be effective in the control of central nervous system toxicity caused by Amantril. For acute overdosing, general supportive measures should be employed along with immediate gastric lavage or induction of emesis. Fluids should be forced, and if necessary, given intravenously. The pH of the urine has been reported to influence the excretion rate of Amantril. Since the excretion rate of Amantril increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. The blood pressure, pulse, respiration and temperature should be monitored. The patient should be observed for hyperactivity and convulsions; if required, sedation, and anticonvulsant therapy should be administered. The patient should be observed for the possible development of arrhythmias and hypotension; if required, appropriate antiarrhythmic and antihypotensive therapy should be given. Electrocardiographic monitoring may be required after ingestion, since malignant tachyarrhythmias can appear after overdose. Therapeutic Class Respiratory viral infections (Influenza) Storage Conditions Keep away from the reach of children. Store in a cool & dry place. Protect from light. Pack Image: Amantril 100 mg Capsule'), -0.009679343821043851), (Document(id='6d61b913-21b3-48f1-959f-9f8278790acd', metadata={}, page_content=\"months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day\\n\\nSyrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.\\n\\ntimes a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Ambeet should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambeet might not be expectorated. Contraindications Contraindicated in known hypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Ambeet should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30C, Keep out of the reach of children.\\n\\nAmbix Syrup Ambroxol Hydrochloride 15 mg/5 ml Modern Pharmaceuticals Ltd. 100 ml bottle:  40.00 Alternate Brands Innovator's Monograph   Indications Ambix is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average\"), -0.011446561179105474), (Document(id='2326c217-21b8-4009-b56d-202184343e94', metadata={}, page_content=\"months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day\\n\\nSyrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.\\n\\ntimes a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily. *       ' Interaction Ambeet should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambeet might not be expectorated. Contraindications Contraindicated in known hypersensitivity to Ambroxol or Bromhexine. Side Effects Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. Pregnancy & Lactation Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet. Precautions & Warnings Ambeet should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution. Therapeutic Class Cough expectorants & mucolytics Storage Conditions Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30C, Keep out of the reach of children.\\n\\nAmbix Syrup Ambroxol Hydrochloride 15 mg/5 ml Modern Pharmaceuticals Ltd. 100 ml bottle:  40.00 Alternate Brands Innovator's Monograph   Indications Ambix is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average\"), -0.011446561179105474), (Document(id='91f7b908-7735-4b5e-b81b-43d44d2e2de9', metadata={}, page_content=\"exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. Amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. Dosage & Administration Parkinson's disease- Adults: The usual dose is 100 mg twice a day when used alone. The initial dose of Amantadine is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary. Occasionally, patients whose responses are not optimal with Amantadine at 200 mg daily may benefit from an increase up to 400 mg daily in divided doses. Dosage for Concomitant Therapy: Some patients who do not respond to anticholinergic antiparkinson drugs may respond to Amantadine. When Amantadine or anticholinergic antiparkinson drugs are each used with marginal benefit, concomitant use may produce additional benefit. When Amantadine and levodopa therapy are initiated concurrently, the patient can exhibit rapid therapeutic benefits. Amantadine dose, should be held constant at 100 mg daily or twice daily while the daily dose of levodopa is gradually increased to optimal benefit. When Amantadine is added to optimal well-tolerated doses of levodopa, additional benefit may result, including smoothing out the fluctuations in improvement which sometimes occur in patients on levodopa alone. Patients who require a reduction in their usual dose of levodopa because of development of side effects may possibly regain lost benefit with the addition of Amantadine. Drug-induced extrapyramidal reactions- Adults: The usual dose is 100 mg twice a day. Occasionally, patients whose responses are not optimal with Amantadine at 200 mg daily may benefit from an increase up to 300 mg daily in divided doses. Prophylaxis and treatment of Influenza A virus illness- Adults: 200 mg/day as single dose or 100 mg twice daily. If CNS effects develop on a once- daily dosage, split dosage schedule may reduce complaints. Elderly over 65 years of age: 100 mg every day. Children: 1 to 9 years of age: 4.4 to 8.8 mg/kg/day; not to exceed 150 mg/day. 9 to 12 years of age: 100 mg twice daily Method of administration: Each capsule is to be taken orally either with or without food.Patients with renal impairment: The dose should be reduced. This can be achieved by either reducing the total daily dose, or by increasing the dosage interval in accordance with the creatinine clearance.Patients with hepatic impairment: Use with caution. *       ' Interaction Concurrent administration of Influ and anticholinergic agents or levodopa may increase confusion, hallucinations, nightmares, gastro-intestinal disturbances, or other atropine-like side effects. Psychotic reactions have been observed in patients receiving Influ and Levodopa. Concurrent administration of Influ and drugs or\"), -0.014413952195363677), (Document(id='4f343e9c-3833-4ca0-81c7-cb501b173863', metadata={}, page_content=\"exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. Amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. Dosage & Administration Parkinson's disease- Adults: The usual dose is 100 mg twice a day when used alone. The initial dose of Amantadine is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary. Occasionally, patients whose responses are not optimal with Amantadine at 200 mg daily may benefit from an increase up to 400 mg daily in divided doses. Dosage for Concomitant Therapy: Some patients who do not respond to anticholinergic antiparkinson drugs may respond to Amantadine. When Amantadine or anticholinergic antiparkinson drugs are each used with marginal benefit, concomitant use may produce additional benefit. When Amantadine and levodopa therapy are initiated concurrently, the patient can exhibit rapid therapeutic benefits. Amantadine dose, should be held constant at 100 mg daily or twice daily while the daily dose of levodopa is gradually increased to optimal benefit. When Amantadine is added to optimal well-tolerated doses of levodopa, additional benefit may result, including smoothing out the fluctuations in improvement which sometimes occur in patients on levodopa alone. Patients who require a reduction in their usual dose of levodopa because of development of side effects may possibly regain lost benefit with the addition of Amantadine. Drug-induced extrapyramidal reactions- Adults: The usual dose is 100 mg twice a day. Occasionally, patients whose responses are not optimal with Amantadine at 200 mg daily may benefit from an increase up to 300 mg daily in divided doses. Prophylaxis and treatment of Influenza A virus illness- Adults: 200 mg/day as single dose or 100 mg twice daily. If CNS effects develop on a once- daily dosage, split dosage schedule may reduce complaints. Elderly over 65 years of age: 100 mg every day. Children: 1 to 9 years of age: 4.4 to 8.8 mg/kg/day; not to exceed 150 mg/day. 9 to 12 years of age: 100 mg twice daily Method of administration: Each capsule is to be taken orally either with or without food.Patients with renal impairment: The dose should be reduced. This can be achieved by either reducing the total daily dose, or by increasing the dosage interval in accordance with the creatinine clearance.Patients with hepatic impairment: Use with caution. *       ' Interaction Concurrent administration of Influ and anticholinergic agents or levodopa may increase confusion, hallucinations, nightmares, gastro-intestinal disturbances, or other atropine-like side effects. Psychotic reactions have been observed in patients receiving Influ and Levodopa. Concurrent administration of Influ and drugs or\"), -0.014413952195363677), (Document(id='2651e265-3f0f-4f0b-b4c6-0d36c9d4d2d0', metadata={}, page_content=\"concomitant use may produce additional benefit. When Amantadine and levodopa therapy are initiated concurrently, the patient can exhibit rapid therapeutic benefits. Amantadine dose, should be held constant at 100 mg daily or twice daily while the daily dose of levodopa is gradually increased to optimal benefit. When Amantadine is added to optimal well-tolerated doses of levodopa, additional benefit may result, including smoothing out the fluctuations in improvement which sometimes occur in patients on levodopa alone. Patients who require a reduction in their usual dose of levodopa because of development of side effects may possibly regain lost benefit with the addition of Amantadine. Drug-induced extrapyramidal reactions- Adults: The usual dose is 100 mg twice a day. Occasionally, patients whose responses are not optimal with Amantadine at 200 mg daily may benefit from an increase up to 300 mg daily in divided doses. Prophylaxis and treatment of Influenza A virus illness- Adults: 200 mg/day as single dose or 100 mg twice daily. If CNS effects develop on a once- daily dosage, split dosage schedule may reduce complaints. Elderly over 65 years of age: 100 mg every day. Children: 1 to 9 years of age: 4.4 to 8.8 mg/kg/day; not to exceed 150 mg/day. 9 to 12 years of age: 100 mg twice daily Method of administration: Each capsule is to be taken orally either with or without food.Patients with renal impairment: The dose should be reduced. This can be achieved by either reducing the total daily dose, or by increasing the dosage interval in accordance with the creatinine clearance.Patients with hepatic impairment: Use with caution. *       ' Interaction Concurrent administration of Influ and anticholinergic agents or levodopa may increase confusion, hallucinations, nightmares, gastro-intestinal disturbances, or other atropine-like side effects. Psychotic reactions have been observed in patients receiving Influ and Levodopa. Concurrent administration of Influ and drugs or substances (e.g. alcohol) acting on the CNS may result in additive CNS toxicity. Close observation is recommended. Contraindications Amantadine is contraindicated in patients with known hypersensitivity to the active substances or to any of the excipients. Side Effects The adverse effects of Influ are generally mild and, when they occur, may diminish or cease after a week or more on the medication. The most commonly reported side effects include nausea, dizziness/lightheadedness, and insomnia. Other side effects may include edema of ankles, livedo reticularis; anxiety, elevation of mood, headache, lethargy, hallucinations, ataxia, slurred speech, blurred vision, loss of concentration, nervousness, depression, myalgia, palpitations, orthostatic hypotension, dry mouth, anorexia, constipation and diaphoresis. Pregnancy & Lactation Pregnancy category C. No well-controlled studies have been done in pregnant women to evaluate Amantadines safety. Amantadine may be used during pregnancy when the potential benefits outweigh the potential but unknown risks to the fetus. Amantadine is excreted into breast milk in low concentrations. As no information is available on the effects in infants, therefore amantadine should be used cautiously in women who are breastfeeding. Precautions & Warnings Influ should not be discontinued abruptly in patients with Parkinson's disease since\"), -0.022208253184180293), (Document(id='22dd0dda-04c5-4ae4-8892-26edddaedaa9', metadata={}, page_content=\"concomitant use may produce additional benefit. When Amantadine and levodopa therapy are initiated concurrently, the patient can exhibit rapid therapeutic benefits. Amantadine dose, should be held constant at 100 mg daily or twice daily while the daily dose of levodopa is gradually increased to optimal benefit. When Amantadine is added to optimal well-tolerated doses of levodopa, additional benefit may result, including smoothing out the fluctuations in improvement which sometimes occur in patients on levodopa alone. Patients who require a reduction in their usual dose of levodopa because of development of side effects may possibly regain lost benefit with the addition of Amantadine. Drug-induced extrapyramidal reactions- Adults: The usual dose is 100 mg twice a day. Occasionally, patients whose responses are not optimal with Amantadine at 200 mg daily may benefit from an increase up to 300 mg daily in divided doses. Prophylaxis and treatment of Influenza A virus illness- Adults: 200 mg/day as single dose or 100 mg twice daily. If CNS effects develop on a once- daily dosage, split dosage schedule may reduce complaints. Elderly over 65 years of age: 100 mg every day. Children: 1 to 9 years of age: 4.4 to 8.8 mg/kg/day; not to exceed 150 mg/day. 9 to 12 years of age: 100 mg twice daily Method of administration: Each capsule is to be taken orally either with or without food.Patients with renal impairment: The dose should be reduced. This can be achieved by either reducing the total daily dose, or by increasing the dosage interval in accordance with the creatinine clearance.Patients with hepatic impairment: Use with caution. *       ' Interaction Concurrent administration of Influ and anticholinergic agents or levodopa may increase confusion, hallucinations, nightmares, gastro-intestinal disturbances, or other atropine-like side effects. Psychotic reactions have been observed in patients receiving Influ and Levodopa. Concurrent administration of Influ and drugs or substances (e.g. alcohol) acting on the CNS may result in additive CNS toxicity. Close observation is recommended. Contraindications Amantadine is contraindicated in patients with known hypersensitivity to the active substances or to any of the excipients. Side Effects The adverse effects of Influ are generally mild and, when they occur, may diminish or cease after a week or more on the medication. The most commonly reported side effects include nausea, dizziness/lightheadedness, and insomnia. Other side effects may include edema of ankles, livedo reticularis; anxiety, elevation of mood, headache, lethargy, hallucinations, ataxia, slurred speech, blurred vision, loss of concentration, nervousness, depression, myalgia, palpitations, orthostatic hypotension, dry mouth, anorexia, constipation and diaphoresis. Pregnancy & Lactation Pregnancy category C. No well-controlled studies have been done in pregnant women to evaluate Amantadines safety. Amantadine may be used during pregnancy when the potential benefits outweigh the potential but unknown risks to the fetus. Amantadine is excreted into breast milk in low concentrations. As no information is available on the effects in infants, therefore amantadine should be used cautiously in women who are breastfeeding. Precautions & Warnings Influ should not be discontinued abruptly in patients with Parkinson's disease since\"), -0.022208253184180293), (Document(id='0f5e9e62-f2ef-4692-9909-9b065bed0039', metadata={}, page_content=\"single dose or 100 mg twice daily. If CNS effects develop on a once- daily dosage, split dosage\\n\\nschedule may reduce complaints. Elderly over 65 years of age: 100 mg every day. Children: 1 to\\n\\n9 years of age: 4.4 to 8.8 mg/kg/day; not to exceed 150 mg/day. 9 to 12 years of age: 100 mg twice daily Method of administration: Each capsule is to be taken orally either with or without food.Patients with renal impairment: The dose should be reduced. This can be achieved by either reducing the total daily dose, or by increasing the dosage interval in accordance with the creatinine clearance.Patients with hepatic impairment: Use with caution. *       ' Interaction Concurrent administration of Amantril and anticholinergic agents or levodopa may increase confusion, hallucinations, nightmares, gastro-intestinal disturbances, or other atropine-like side effects. Psychotic reactions have been observed in patients receiving Amantril and Levodopa. Concurrent administration of Amantril and drugs or substances (e.g. alcohol) acting on the CNS may result in additive CNS toxicity. Close observation is recommended. Contraindications Amantadine is contraindicated in patients with known hypersensitivity to the active substances or to any of the excipients. Side Effects The adverse effects of Amantril are generally mild and, when they occur, may diminish or cease after a week or more on the medication. The most commonly reported side effects include nausea, dizziness/lightheadedness, and insomnia. Other side effects may include edema of ankles, livedo reticularis; anxiety, elevation of mood, headache, lethargy, hallucinations, ataxia, slurred speech, blurred vision, loss of concentration, nervousness, depression, myalgia, palpitations, orthostatic hypotension, dry mouth, anorexia, constipation and diaphoresis. Pregnancy & Lactation Pregnancy category C. No well-controlled studies have been done in pregnant women to evaluate Amantadines safety. Amantadine may be used during pregnancy when the potential benefits outweigh the potential but unknown risks to the fetus. Amantadine is excreted into breast milk in low concentrations. As no information is available on the effects in infants, therefore amantadine should be used cautiously in women who are breastfeeding. Precautions & Warnings Amantril should not be discontinued abruptly in patients with Parkinson's disease since a few patients have experienced a parkinsonian crisis, i.e., a sudden marked clinical deterioration, when this medication was suddenly stopped. The dose of anticholinergic drugs or of Amantril should be reduced if atropine-like effects appear when these drugs are used concurrently. Abrupt discontinuation may also precipitate delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression and slurred speech. Overdose Effects Deaths have been reported from overdose with Amantril. The lowest reported acute lethal dose was 1 gram. Because some patients have attempted suicide by overdosing with Amantril, prescriptions should be written for the smallest quantity consistent with good patient management.Acute toxicity may be attributable to the anticholinergic effects of Amantril. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress have been reported; renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects include\"), -0.024716833607548727), (Document(id='12a99306-17b3-4aeb-adf6-77d1e6e2104f', metadata={}, page_content=\"single dose or 100 mg twice daily. If CNS effects develop on a once- daily dosage, split dosage\\n\\nschedule may reduce complaints. Elderly over 65 years of age: 100 mg every day. Children: 1 to\\n\\n9 years of age: 4.4 to 8.8 mg/kg/day; not to exceed 150 mg/day. 9 to 12 years of age: 100 mg twice daily Method of administration: Each capsule is to be taken orally either with or without food.Patients with renal impairment: The dose should be reduced. This can be achieved by either reducing the total daily dose, or by increasing the dosage interval in accordance with the creatinine clearance.Patients with hepatic impairment: Use with caution. *       ' Interaction Concurrent administration of Amantril and anticholinergic agents or levodopa may increase confusion, hallucinations, nightmares, gastro-intestinal disturbances, or other atropine-like side effects. Psychotic reactions have been observed in patients receiving Amantril and Levodopa. Concurrent administration of Amantril and drugs or substances (e.g. alcohol) acting on the CNS may result in additive CNS toxicity. Close observation is recommended. Contraindications Amantadine is contraindicated in patients with known hypersensitivity to the active substances or to any of the excipients. Side Effects The adverse effects of Amantril are generally mild and, when they occur, may diminish or cease after a week or more on the medication. The most commonly reported side effects include nausea, dizziness/lightheadedness, and insomnia. Other side effects may include edema of ankles, livedo reticularis; anxiety, elevation of mood, headache, lethargy, hallucinations, ataxia, slurred speech, blurred vision, loss of concentration, nervousness, depression, myalgia, palpitations, orthostatic hypotension, dry mouth, anorexia, constipation and diaphoresis. Pregnancy & Lactation Pregnancy category C. No well-controlled studies have been done in pregnant women to evaluate Amantadines safety. Amantadine may be used during pregnancy when the potential benefits outweigh the potential but unknown risks to the fetus. Amantadine is excreted into breast milk in low concentrations. As no information is available on the effects in infants, therefore amantadine should be used cautiously in women who are breastfeeding. Precautions & Warnings Amantril should not be discontinued abruptly in patients with Parkinson's disease since a few patients have experienced a parkinsonian crisis, i.e., a sudden marked clinical deterioration, when this medication was suddenly stopped. The dose of anticholinergic drugs or of Amantril should be reduced if atropine-like effects appear when these drugs are used concurrently. Abrupt discontinuation may also precipitate delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression and slurred speech. Overdose Effects Deaths have been reported from overdose with Amantril. The lowest reported acute lethal dose was 1 gram. Because some patients have attempted suicide by overdosing with Amantril, prescriptions should be written for the smallest quantity consistent with good patient management.Acute toxicity may be attributable to the anticholinergic effects of Amantril. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress have been reported; renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects include\"), -0.024716833607548727), (Document(id='f7af9228-9a19-44fe-aafe-ada3996cccc1', metadata={}, page_content=\"partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are\\n\\nuncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or\\n\\nregurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\\n\\nfirst trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nPharmacid Plus Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 400 mg+400 mg+30 mg Pharmadesh Laboratories Ltd. Unit Price:  1.13 (200's pack:  226.00) Also available as: (200 mg+400 mg+30 mg)/5 ml (Suspension) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg\"), -0.031757043182808475), (Document(id='7b107971-6185-4e72-8b5d-ce5d5d4e9ee8', metadata={}, page_content=\"partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are\\n\\nuncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or\\n\\nregurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\\n\\nfirst trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nPharmacid Plus Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 400 mg+400 mg+30 mg Pharmadesh Laboratories Ltd. Unit Price:  1.13 (200's pack:  226.00) Also available as: (200 mg+400 mg+30 mg)/5 ml (Suspension) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg\"), -0.031757043182808475), (Document(id='6d8d89ea-dd60-4469-968f-f9aae61b8c07', metadata={}, page_content=\"been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited. Precautions & Warnings Avoid Pelverin in patients with intestinal obstruction or paralytic ileus. Use in Special Populations Children under 12 years: Not recommended Overdose Effects Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension. Therapeutic Class Anticholinergics Storage Conditions Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25C temperature. Pack Image: Pelverin 60 mg Tablet\\n\\nSpasverin Tablet Pack Image Alverine Citrate 60 mg Beacon Pharmaceuticals PLC Unit Price:  5.02 (5 x 10:  251.00) Strip Price:  50.20 Alternate Brands Innovator's Monograph   Indications Spasverin is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle *       ' Pharmacology Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine Citrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea). Dosage & Administration Adult: Orally: 60-120 mg 1-3 times daily. *       ' Interaction There are no drug interactions reported with this medicine. Contraindications Paralytic ileus or known hypersensitivity to any of the ingredients. Side Effects Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions. Pregnancy & Lactation Although no teratogenic effects have been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited. Precautions & Warnings Avoid Spasverin in patients with intestinal obstruction or paralytic ileus. Use in Special Populations Children under 12 years: Not recommended Overdose Effects Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension. Therapeutic Class Anticholinergics Storage Conditions Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25C temperature. Pack Image: Spasverin 60 mg Tablet\\n\\nAmbrisan Tablet Pack Image Ambrisentan 5 mg Square Pharmaceuticals PLC Unit Price:  40.13 (2 x 10:  802.60) Strip Price:  401.30 Alternate Brands Innovator's Monograph Indications Ambrisan is indicated for the treatment of Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. *       ' Pharmacology Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and\"), -0.032670786858524536), (Document(id='6015fbe3-85c1-4e27-98f9-fea120aefd02', metadata={}, page_content=\"been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited. Precautions & Warnings Avoid Pelverin in patients with intestinal obstruction or paralytic ileus. Use in Special Populations Children under 12 years: Not recommended Overdose Effects Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension. Therapeutic Class Anticholinergics Storage Conditions Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25C temperature. Pack Image: Pelverin 60 mg Tablet\\n\\nSpasverin Tablet Pack Image Alverine Citrate 60 mg Beacon Pharmaceuticals PLC Unit Price:  5.02 (5 x 10:  251.00) Strip Price:  50.20 Alternate Brands Innovator's Monograph   Indications Spasverin is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle *       ' Pharmacology Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine Citrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea). Dosage & Administration Adult: Orally: 60-120 mg 1-3 times daily. *       ' Interaction There are no drug interactions reported with this medicine. Contraindications Paralytic ileus or known hypersensitivity to any of the ingredients. Side Effects Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions. Pregnancy & Lactation Although no teratogenic effects have been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited. Precautions & Warnings Avoid Spasverin in patients with intestinal obstruction or paralytic ileus. Use in Special Populations Children under 12 years: Not recommended Overdose Effects Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension. Therapeutic Class Anticholinergics Storage Conditions Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25C temperature. Pack Image: Spasverin 60 mg Tablet\\n\\nAmbrisan Tablet Pack Image Ambrisentan 5 mg Square Pharmaceuticals PLC Unit Price:  40.13 (2 x 10:  802.60) Strip Price:  401.30 Alternate Brands Innovator's Monograph Indications Ambrisan is indicated for the treatment of Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. *       ' Pharmacology Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and\"), -0.032670786858524536), (Document(id='08f3ebf4-4d1e-4fd2-a954-98c47c1f2927', metadata={}, page_content='a few patients have experienced a parkinsonian crisis, i.e., a sudden marked clinical\\n\\ndeterioration, when this medication was suddenly stopped. The dose of anticholinergic drugs or\\n\\nof Influ should be reduced if atropine-like effects appear when these drugs are used\\n\\nconcurrently. Abrupt discontinuation may also precipitate delirium, agitation, delusions,\\n\\nhallucinations, paranoid reaction, stupor, anxiety, depression and slurred speech. Overdose\\n\\nEffects Deaths have been reported from overdose with Influ. The lowest reported acute lethal\\n\\ndose was 1 gram. Because some patients have attempted suicide by overdosing with Influ, prescriptions should be written for the smallest quantity consistent with good patient management.Acute toxicity may be attributable to the anticholinergic effects of Influ. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress have been reported; renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects include insomnia, anxiety, agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, gait abnormality, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucinations, psychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has also been observed.There is no specific antidote for an overdose of Influ. However, slowly administered intravenous physostigmine in 1 and 2 mg doses in an adult at 1- to 2-hour intervals and 0.5 mg doses in a child at 5- to 10-minute intervals up to a maximum of 2 mg/hour have been reported to be effective in the control of central nervous system toxicity caused by Influ. For acute overdosing, general supportive measures should be employed along with immediate gastric lavage or induction of emesis. Fluids should be forced, and if necessary, given intravenously. The pH of the urine has been reported to influence the excretion rate of Influ. Since the excretion rate of Influ increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. The blood pressure, pulse, respiration and temperature should be monitored. The patient should be observed for hyperactivity and convulsions; if required, sedation, and anticonvulsant therapy should be administered. The patient should be observed for the possible development of arrhythmias and hypotension; if required, appropriate antiarrhythmic and antihypotensive therapy should be given. Electrocardiographic monitoring may be required after ingestion, since malignant tachyarrhythmias can appear after overdose. Therapeutic Class Respiratory viral infections (Influenza) Storage Conditions Keep away from the reach of children. Store in a cool & dry'), -0.03575989797328205), (Document(id='ea7a125a-beec-4103-aa00-25f18fe3d3af', metadata={}, page_content='a few patients have experienced a parkinsonian crisis, i.e., a sudden marked clinical\\n\\ndeterioration, when this medication was suddenly stopped. The dose of anticholinergic drugs or\\n\\nof Influ should be reduced if atropine-like effects appear when these drugs are used\\n\\nconcurrently. Abrupt discontinuation may also precipitate delirium, agitation, delusions,\\n\\nhallucinations, paranoid reaction, stupor, anxiety, depression and slurred speech. Overdose\\n\\nEffects Deaths have been reported from overdose with Influ. The lowest reported acute lethal\\n\\ndose was 1 gram. Because some patients have attempted suicide by overdosing with Influ, prescriptions should be written for the smallest quantity consistent with good patient management.Acute toxicity may be attributable to the anticholinergic effects of Influ. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress have been reported; renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects include insomnia, anxiety, agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, gait abnormality, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucinations, psychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has also been observed.There is no specific antidote for an overdose of Influ. However, slowly administered intravenous physostigmine in 1 and 2 mg doses in an adult at 1- to 2-hour intervals and 0.5 mg doses in a child at 5- to 10-minute intervals up to a maximum of 2 mg/hour have been reported to be effective in the control of central nervous system toxicity caused by Influ. For acute overdosing, general supportive measures should be employed along with immediate gastric lavage or induction of emesis. Fluids should be forced, and if necessary, given intravenously. The pH of the urine has been reported to influence the excretion rate of Influ. Since the excretion rate of Influ increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. The blood pressure, pulse, respiration and temperature should be monitored. The patient should be observed for hyperactivity and convulsions; if required, sedation, and anticonvulsant therapy should be administered. The patient should be observed for the possible development of arrhythmias and hypotension; if required, appropriate antiarrhythmic and antihypotensive therapy should be given. Electrocardiographic monitoring may be required after ingestion, since malignant tachyarrhythmias can appear after overdose. Therapeutic Class Respiratory viral infections (Influenza) Storage Conditions Keep away from the reach of children. Store in a cool & dry'), -0.03575989797328205), (Document(id='e49e8f92-c700-4528-8167-59fdc77a7d47', metadata={}, page_content='tachyarrhythmias can appear after overdose. Therapeutic Class Respiratory viral infections\\n\\n(Influenza) Storage Conditions Keep away from the reach of children. Store in a cool & dry'), -0.03802992723407872), (Document(id='9be55cf7-f745-40c4-b084-27d78433836e', metadata={}, page_content='tachyarrhythmias can appear after overdose. Therapeutic Class Respiratory viral infections\\n\\n(Influenza) Storage Conditions Keep away from the reach of children. Store in a cool & dry'), -0.03802992723407872), (Document(id='6de14784-9a4b-41d2-921f-60d4bb3fb0f0', metadata={}, page_content=\"place. Protect from light.\\n\\nA-Mycin Lotion Pack Image Erythromycin 3% Aristopharma Ltd. 25 ml bottle:  120.00 Alternate Brands Innovator's Monograph   Indications For topical treatment of acne, pimples & bacterial skin infections susceptible to A-Mycin. *       ' Pharmacology Erythromycin is a bacteriostatic macrolide antibiotic. But may be bactericidal in high concentrations. Although the mechanism by which Erythromycin acts in reducing the inflammatory lesions of acne vulgaris is unknown, it is presumably due to the antibiotic action of the drug. Dosage & Administration Apply in morning and evening to the affected areas. Before applying thoroughly wash with warm water and soap, rinse and pat dry all areas to be treated. Apply with fingertips or applicator. Wash hands after use. Spread the medication lightly rather than rubbing it in. Acne lesions on the face, neck, shoulders, chest and back may be treated in this manner. Additional containers may be used, if needed. Each container should be used once and discarded. *       ' Interaction Clindamycin interacts with A-Mycin. Contraindications Hypersensitivity to Erythromycin or to any of the other ingredients of the lotion. Side Effects Erythema, desquamation, burning sensation, eye irritation, tenderness, dryness, oily skin etc. Pregnancy & Lactation Safety for use during pregnancy has not been established. Use only when the potential benefits outweigh potential hazards to the fetus. Erythromycin is excreted in breast milk. Exercise caution when administering to a nursing mother. Precautions & Warnings For external use only. Keep away from eyes, nose, mouth and other mucous membrane. Use of antibiotics (especially prolonged or repeated therapy) may result in bacterial or fungal overgrowth of non-susceptible organisms. Such overgrowth may lead to a secondary infection. Take appropriate measures if superinfections occur. Use in Special Populations Safety and effectiveness in children less than 12 years have not been established. Therapeutic Class Topical antibiotics for Acne Storage Conditions Keep below 25C temperature, away from light & moisture. Keep out of the reach of children. Pack Image: A-Mycin 3% Lotion\\n\\nEromycin Lotion Pack Image Erythromycin 3% Square Pharmaceuticals PLC 25 ml bottle:  120.37 Alternate Brands Innovator's Monograph   Indications For topical treatment of acne, pimples & bacterial skin infections susceptible to Eromycin. *       ' Pharmacology Erythromycin is a bacteriostatic macrolide antibiotic. But may be bactericidal in high concentrations. Although the mechanism by which Erythromycin acts in reducing the inflammatory lesions of acne vulgaris is unknown, it is presumably due to the antibiotic action of the drug. Dosage & Administration Apply in morning and evening to the affected areas. Before applying thoroughly wash with warm water and soap, rinse and pat dry all areas to be treated. Apply with fingertips or applicator. Wash hands after use. Spread the medication lightly rather than rubbing it in. Acne lesions on the face, neck, shoulders, chest and back may be treated in this manner. Additional containers may be used, if needed. Each container should be used once and discarded. *       ' Interaction Clindamycin interacts with Eromycin. Contraindications Hypersensitivity to Erythromycin or to any of the other ingredients of the lotion. Side Effects Erythema, desquamation, burning sensation, eye irritation, tenderness, dryness, oily skin etc. Pregnancy & Lactation Safety for use during pregnancy has not been established. Use only when the potential benefits outweigh potential hazards to the fetus. Erythromycin is excreted in breast\"), -0.05043307040125877), (Document(id='6d92c4e7-50f5-46e8-b226-064f8c3200f1', metadata={}, page_content=\"place. Protect from light.\\n\\nA-Mycin Lotion Pack Image Erythromycin 3% Aristopharma Ltd. 25 ml bottle:  120.00 Alternate Brands Innovator's Monograph   Indications For topical treatment of acne, pimples & bacterial skin infections susceptible to A-Mycin. *       ' Pharmacology Erythromycin is a bacteriostatic macrolide antibiotic. But may be bactericidal in high concentrations. Although the mechanism by which Erythromycin acts in reducing the inflammatory lesions of acne vulgaris is unknown, it is presumably due to the antibiotic action of the drug. Dosage & Administration Apply in morning and evening to the affected areas. Before applying thoroughly wash with warm water and soap, rinse and pat dry all areas to be treated. Apply with fingertips or applicator. Wash hands after use. Spread the medication lightly rather than rubbing it in. Acne lesions on the face, neck, shoulders, chest and back may be treated in this manner. Additional containers may be used, if needed. Each container should be used once and discarded. *       ' Interaction Clindamycin interacts with A-Mycin. Contraindications Hypersensitivity to Erythromycin or to any of the other ingredients of the lotion. Side Effects Erythema, desquamation, burning sensation, eye irritation, tenderness, dryness, oily skin etc. Pregnancy & Lactation Safety for use during pregnancy has not been established. Use only when the potential benefits outweigh potential hazards to the fetus. Erythromycin is excreted in breast milk. Exercise caution when administering to a nursing mother. Precautions & Warnings For external use only. Keep away from eyes, nose, mouth and other mucous membrane. Use of antibiotics (especially prolonged or repeated therapy) may result in bacterial or fungal overgrowth of non-susceptible organisms. Such overgrowth may lead to a secondary infection. Take appropriate measures if superinfections occur. Use in Special Populations Safety and effectiveness in children less than 12 years have not been established. Therapeutic Class Topical antibiotics for Acne Storage Conditions Keep below 25C temperature, away from light & moisture. Keep out of the reach of children. Pack Image: A-Mycin 3% Lotion\\n\\nEromycin Lotion Pack Image Erythromycin 3% Square Pharmaceuticals PLC 25 ml bottle:  120.37 Alternate Brands Innovator's Monograph   Indications For topical treatment of acne, pimples & bacterial skin infections susceptible to Eromycin. *       ' Pharmacology Erythromycin is a bacteriostatic macrolide antibiotic. But may be bactericidal in high concentrations. Although the mechanism by which Erythromycin acts in reducing the inflammatory lesions of acne vulgaris is unknown, it is presumably due to the antibiotic action of the drug. Dosage & Administration Apply in morning and evening to the affected areas. Before applying thoroughly wash with warm water and soap, rinse and pat dry all areas to be treated. Apply with fingertips or applicator. Wash hands after use. Spread the medication lightly rather than rubbing it in. Acne lesions on the face, neck, shoulders, chest and back may be treated in this manner. Additional containers may be used, if needed. Each container should be used once and discarded. *       ' Interaction Clindamycin interacts with Eromycin. Contraindications Hypersensitivity to Erythromycin or to any of the other ingredients of the lotion. Side Effects Erythema, desquamation, burning sensation, eye irritation, tenderness, dryness, oily skin etc. Pregnancy & Lactation Safety for use during pregnancy has not been established. Use only when the potential benefits outweigh potential hazards to the fetus. Erythromycin is excreted in breast\"), -0.05043307040125877), (Document(id='76318cd6-df24-45ea-9601-67fe095c5b81', metadata={}, page_content=\"uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or\\n\\nregurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\\n\\nfirst trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nRemacid Plus Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 200 mg+200 mg+30 mg Reman Drug Laboratories Ltd. Unit Price:  0.78 (200's pack:  156.00) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg\\n\\nBP: 400 mg Simethicone USP: 30 mg Each 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 200 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 400 mg Simethicone USP: 30 mg Pharmacology This is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled.This is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. Dosage & Administration Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. *       ' Interaction All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. Contraindications This should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\"), -0.07242934205170037), (Document(id='f5f1ebb5-9cea-4a25-86ee-23a9fe01860e', metadata={}, page_content=\"uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or\\n\\nregurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\\n\\nfirst trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nRecocid Plus Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone\\n\\n400 mg+400 mg+30 mg Rephco Pharmaceuticals Ltd. Unit Price:  1.00 (200's pack:  200.00) Also available as: (200 mg+400 mg+30 mg)/5 ml (Suspension) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg Each 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 200 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 400 mg Simethicone USP: 30 mg Pharmacology This is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled.This is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. Dosage & Administration Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. *       ' Interaction All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. Contraindications This should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are\"), -0.07242934205170037), (Document(id='70cc99a6-46a1-4589-aa4a-85c7768bd62d', metadata={}, page_content=\"uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or\\n\\nregurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\\n\\nfirst trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nNocid Plus Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 200 mg+200 mg+30 mg Medimet Pharmaceuticals Ltd. Unit Price:  0.90 (200's pack:  180.00) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg\"), -0.07242934205170037), (Document(id='9131d4ba-01eb-4669-baea-9ee744520b51', metadata={}, page_content=\"uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or\\n\\nregurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\\n\\nfirst trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nNocid Plus Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 200 mg+200 mg+30 mg Medimet Pharmaceuticals Ltd. Unit Price:  0.90 (200's pack:  180.00) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg\"), -0.07242934205170037), (Document(id='9c2366bd-575d-4442-b984-38b42e3e2f63', metadata={}, page_content=\"uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or\\n\\nregurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\\n\\nfirst trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nRecocid Plus Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone\\n\\n400 mg+400 mg+30 mg Rephco Pharmaceuticals Ltd. Unit Price:  1.00 (200's pack:  200.00) Also available as: (200 mg+400 mg+30 mg)/5 ml (Suspension) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg Each 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 200 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 400 mg Simethicone USP: 30 mg Pharmacology This is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled.This is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. Dosage & Administration Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. *       ' Interaction All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. Contraindications This should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are\"), -0.07242934205170037), (Document(id='64f91ac4-1ef1-487c-98de-e701c2b0fdbe', metadata={}, page_content=\"uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or\\n\\nregurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\\n\\nfirst trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nRemacid Plus Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 200 mg+200 mg+30 mg Reman Drug Laboratories Ltd. Unit Price:  0.78 (200's pack:  156.00) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg\\n\\nBP: 400 mg Simethicone USP: 30 mg Each 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 200 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 400 mg Simethicone USP: 30 mg Pharmacology This is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled.This is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. Dosage & Administration Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. *       ' Interaction All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. Contraindications This should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the\"), -0.07242934205170037), (Document(id='f8d98cdf-b09b-41ac-8783-d607226aa90d', metadata={}, page_content='possibility of pulmonary veno-occlusive disease should be considered, and if con_rmed.\\n\\nAmbrisan should be discontinued. Hematological Changes: Decreases in hemoglobin\\n\\nconcentration and hematocrit have followed administration of other endothelin receptor\\n\\nantagonists and were observed in clinical studies with Ambrisan.Hepatic impairment: Ambrisan\\n\\nis not recommended in patients with moderate or severe hepatic impairment. Therapeutic Class\\n\\nAnti-hypertensive, Endothelin receptor antagonist Storage Conditions Store in a cool and dry place, below 30C. Protect from light and moisture. Pack Image: Ambrisan 5 mg Tablet\\n\\nAmantril Capsule Pack Image Amantadine Hydrochloride 100 mg ACI Limited Unit Price: '), -0.07722051149672171), (Document(id='6840aa5e-fc9f-4dd9-ace2-4e44f56dc39b', metadata={}, page_content='possibility of pulmonary veno-occlusive disease should be considered, and if con_rmed.\\n\\nAmbrisan should be discontinued. Hematological Changes: Decreases in hemoglobin\\n\\nconcentration and hematocrit have followed administration of other endothelin receptor\\n\\nantagonists and were observed in clinical studies with Ambrisan.Hepatic impairment: Ambrisan\\n\\nis not recommended in patients with moderate or severe hepatic impairment. Therapeutic Class\\n\\nAnti-hypertensive, Endothelin receptor antagonist Storage Conditions Store in a cool and dry place, below 30C. Protect from light and moisture. Pack Image: Ambrisan 5 mg Tablet\\n\\nAmantril Capsule Pack Image Amantadine Hydrochloride 100 mg ACI Limited Unit Price: '), -0.07722051149672171), (Document(id='4d9fdcb8-5aac-4169-9828-8581a881f7b5', metadata={}, page_content='substances (e.g. alcohol) acting on the CNS may result in additive CNS toxicity. Close\\n\\nobservation is recommended. Contraindications Amantadine is contraindicated in patients with\\n\\nknown hypersensitivity to the active substances or to any of the excipients. Side Effects The\\n\\nadverse effects of Influ are generally mild and, when they occur, may diminish or cease after a\\n\\nweek or more on the medication. The most commonly reported side effects include nausea,\\n\\ndizziness/lightheadedness, and insomnia. Other side effects may include edema of ankles,\\n\\nlivedo reticularis; anxiety, elevation of mood, headache, lethargy, hallucinations, ataxia, slurred\\n\\nspeech, blurred vision, loss of concentration, nervousness, depression, myalgia, palpitations,'), -0.08572009784851975), (Document(id='32b4e2be-4646-49ab-a54b-097097af6e7b', metadata={}, page_content='substances (e.g. alcohol) acting on the CNS may result in additive CNS toxicity. Close\\n\\nobservation is recommended. Contraindications Amantadine is contraindicated in patients with\\n\\nknown hypersensitivity to the active substances or to any of the excipients. Side Effects The\\n\\nadverse effects of Influ are generally mild and, when they occur, may diminish or cease after a\\n\\nweek or more on the medication. The most commonly reported side effects include nausea,\\n\\ndizziness/lightheadedness, and insomnia. Other side effects may include edema of ankles,\\n\\nlivedo reticularis; anxiety, elevation of mood, headache, lethargy, hallucinations, ataxia, slurred\\n\\nspeech, blurred vision, loss of concentration, nervousness, depression, myalgia, palpitations,'), -0.08572009784851975), (Document(id='73cbece3-6f21-412c-af7a-48f15a069f8b', metadata={}, page_content=\"temperature.\\n\\nDismonal Tablet Pack Image Alverine Citrate 60 mg Opsonin Pharma Ltd. Unit Price:  5.00 (5 x 10:  250.00) Strip Price:  50.00 Alternate Brands Innovator's Monograph   Indications Dismonal is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle *       ' Pharmacology Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine Citrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea). Dosage & Administration Adult: Orally: 60-120 mg 1-3 times daily. *       ' Interaction There are no drug interactions reported with this medicine. Contraindications Paralytic ileus or known hypersensitivity to any of the ingredients. Side Effects Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions. Pregnancy & Lactation Although no teratogenic effects have been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited. Precautions & Warnings Avoid Dismonal in patients with intestinal obstruction or paralytic ileus. Use in Special Populations Children under 12 years: Not recommended Overdose Effects Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension. Therapeutic Class Anticholinergics Storage Conditions Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25C temperature. Pack Image: Dismonal 60 mg Tablet\\n\\nPelverin Tablet Pack Image Alverine Citrate 60 mg Popular Pharmaceuticals Ltd. Unit Price:  5.00 (5 x 10:  250.00) Strip Price:  50.00 Alternate Brands Innovator's Monograph   Indications Pelverin is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle *       ' Pharmacology Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine Citrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea). Dosage & Administration Adult: Orally: 60-120 mg 1-3 times daily. *       ' Interaction There are no drug interactions reported with this medicine. Contraindications Paralytic ileus or known hypersensitivity to any of the ingredients. Side Effects Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions. Pregnancy & Lactation Although no teratogenic effects have\"), -0.08810603094272129), (Document(id='365232b6-2001-49f4-83c6-1aa2095f44df', metadata={}, page_content=\"temperature.\\n\\nDismonal Tablet Pack Image Alverine Citrate 60 mg Opsonin Pharma Ltd. Unit Price:  5.00 (5 x 10:  250.00) Strip Price:  50.00 Alternate Brands Innovator's Monograph   Indications Dismonal is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle *       ' Pharmacology Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine Citrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea). Dosage & Administration Adult: Orally: 60-120 mg 1-3 times daily. *       ' Interaction There are no drug interactions reported with this medicine. Contraindications Paralytic ileus or known hypersensitivity to any of the ingredients. Side Effects Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions. Pregnancy & Lactation Although no teratogenic effects have been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited. Precautions & Warnings Avoid Dismonal in patients with intestinal obstruction or paralytic ileus. Use in Special Populations Children under 12 years: Not recommended Overdose Effects Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension. Therapeutic Class Anticholinergics Storage Conditions Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25C temperature. Pack Image: Dismonal 60 mg Tablet\\n\\nPelverin Tablet Pack Image Alverine Citrate 60 mg Popular Pharmaceuticals Ltd. Unit Price:  5.00 (5 x 10:  250.00) Strip Price:  50.00 Alternate Brands Innovator's Monograph   Indications Pelverin is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle *       ' Pharmacology Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine Citrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea). Dosage & Administration Adult: Orally: 60-120 mg 1-3 times daily. *       ' Interaction There are no drug interactions reported with this medicine. Contraindications Paralytic ileus or known hypersensitivity to any of the ingredients. Side Effects Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions. Pregnancy & Lactation Although no teratogenic effects have\"), -0.08810603094272129), (Document(id='5938bd1c-b9fc-4783-b769-37c3054535ea', metadata={}, page_content=\"exceeding 30C, Keep out of the reach of children. Pack Image: Acorex 15 mg Syrup\\n\\nAmbeet Syrup Ambroxol Hydrochloride 15 mg/5 ml Ethical Drugs Limited 100 ml bottle:  40.00\\n\\nAlso available as: 75 mg (SR Capsule) Alternate Brands Innovator's Monograph   Indications Ambeet is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2\"), -0.12221901577786287), (Document(id='65788db6-2983-4743-9b1a-ff807b09299e', metadata={}, page_content=\"exceeding 30C, Keep out of the reach of children. Pack Image: Acorex 15 mg Syrup\\n\\nAmbeet Syrup Ambroxol Hydrochloride 15 mg/5 ml Ethical Drugs Limited 100 ml bottle:  40.00\\n\\nAlso available as: 75 mg (SR Capsule) Alternate Brands Innovator's Monograph   Indications Ambeet is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. *       ' Pharmacology Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency. Dosage & Administration Average daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2\"), -0.12221901577786287), (Document(id='42411303-b08e-44f0-bed1-8c77f00c8249', metadata={}, page_content=\"orthostatic hypotension, dry mouth, anorexia, constipation and diaphoresis. Pregnancy &\\n\\nLactation Pregnancy category C. No well-controlled studies have been done in pregnant women to evaluate Amantadines safety. Amantadine may be used during pregnancy when the potential benefits outweigh the potential but unknown risks to the fetus. Amantadine is excreted into breast milk in low concentrations. As no information is available on the effects in infants, therefore amantadine should be used cautiously in women who are breastfeeding. Precautions & Warnings Influ should not be discontinued abruptly in patients with Parkinson's disease since a few patients have experienced a parkinsonian crisis, i.e., a sudden marked clinical deterioration, when this medication was suddenly stopped. The dose of anticholinergic drugs or of Influ should be reduced if atropine-like effects appear when these drugs are used concurrently. Abrupt discontinuation may also precipitate delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression and slurred speech. Overdose Effects Deaths have been reported from overdose with Influ. The lowest reported acute lethal dose was 1 gram. Because some patients have attempted suicide by overdosing with Influ, prescriptions should be written for the smallest quantity consistent with good patient management.Acute toxicity may be attributable to the anticholinergic effects of Influ. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress have been reported; renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects include insomnia, anxiety, agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, gait abnormality, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucinations, psychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has also been observed.There is no specific antidote for an overdose of Influ. However, slowly administered intravenous physostigmine in 1 and 2 mg doses in an adult at 1- to 2-hour intervals and 0.5 mg doses in a child at 5- to 10-minute intervals up to a maximum of 2 mg/hour have been reported to be effective in the control of central nervous system toxicity caused by Influ. For acute overdosing, general supportive measures should be employed along with immediate gastric lavage or induction of emesis. Fluids should be forced, and if necessary, given intravenously. The pH of the urine has been reported to influence the excretion rate of Influ. Since the excretion rate of Influ increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. The blood pressure, pulse, respiration and temperature should be monitored. The patient should be observed for hyperactivity and convulsions; if required, sedation, and anticonvulsant therapy should be administered. The patient should be observed for the possible development of arrhythmias and hypotension; if required, appropriate antiarrhythmic and antihypotensive therapy should be given. Electrocardiographic monitoring may be required after ingestion, since malignant\"), -0.1283464089080737), (Document(id='ad016d51-5dfd-4b7c-b222-5f92d9b9b5ce', metadata={}, page_content=\"orthostatic hypotension, dry mouth, anorexia, constipation and diaphoresis. Pregnancy &\\n\\nLactation Pregnancy category C. No well-controlled studies have been done in pregnant women to evaluate Amantadines safety. Amantadine may be used during pregnancy when the potential benefits outweigh the potential but unknown risks to the fetus. Amantadine is excreted into breast milk in low concentrations. As no information is available on the effects in infants, therefore amantadine should be used cautiously in women who are breastfeeding. Precautions & Warnings Influ should not be discontinued abruptly in patients with Parkinson's disease since a few patients have experienced a parkinsonian crisis, i.e., a sudden marked clinical deterioration, when this medication was suddenly stopped. The dose of anticholinergic drugs or of Influ should be reduced if atropine-like effects appear when these drugs are used concurrently. Abrupt discontinuation may also precipitate delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression and slurred speech. Overdose Effects Deaths have been reported from overdose with Influ. The lowest reported acute lethal dose was 1 gram. Because some patients have attempted suicide by overdosing with Influ, prescriptions should be written for the smallest quantity consistent with good patient management.Acute toxicity may be attributable to the anticholinergic effects of Influ. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress have been reported; renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects include insomnia, anxiety, agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, gait abnormality, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucinations, psychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has also been observed.There is no specific antidote for an overdose of Influ. However, slowly administered intravenous physostigmine in 1 and 2 mg doses in an adult at 1- to 2-hour intervals and 0.5 mg doses in a child at 5- to 10-minute intervals up to a maximum of 2 mg/hour have been reported to be effective in the control of central nervous system toxicity caused by Influ. For acute overdosing, general supportive measures should be employed along with immediate gastric lavage or induction of emesis. Fluids should be forced, and if necessary, given intravenously. The pH of the urine has been reported to influence the excretion rate of Influ. Since the excretion rate of Influ increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. The blood pressure, pulse, respiration and temperature should be monitored. The patient should be observed for hyperactivity and convulsions; if required, sedation, and anticonvulsant therapy should be administered. The patient should be observed for the possible development of arrhythmias and hypotension; if required, appropriate antiarrhythmic and antihypotensive therapy should be given. Electrocardiographic monitoring may be required after ingestion, since malignant\"), -0.1283464089080737), (Document(id='2f75c25d-4240-418b-92e8-aca906760850', metadata={}, page_content=\"Alve Tablet Pack Image Alverine Citrate 60 mg Orion Pharma Ltd. Unit Price:  5.01 (5 x 10:  250.50) Strip Price:  50.10 Alternate Brands Innovator's Monograph   Indications Alve is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle *       ' Pharmacology Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine\\n\\nCitrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea). Dosage & Administration Adult: Orally: 60-120 mg 1-3 times daily. *       ' Interaction There are no drug interactions reported with this medicine. Contraindications Paralytic ileus or known hypersensitivity to any of the ingredients. Side Effects Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions. Pregnancy & Lactation Although no teratogenic effects have been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited. Precautions & Warnings Avoid Alve in patients with intestinal obstruction or paralytic ileus. Use in Special Populations Children under 12 years: Not recommended Overdose Effects Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension. Therapeutic Class Anticholinergics Storage Conditions Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25C temperature. Pack Image: Alve 60 mg Tablet\"), -0.13551879100026354), (Document(id='c90f5bbd-e808-42e7-aad8-97aad8f7fae4', metadata={}, page_content=\"Alve Tablet Pack Image Alverine Citrate 60 mg Orion Pharma Ltd. Unit Price:  5.01 (5 x 10:  250.50) Strip Price:  50.10 Alternate Brands Innovator's Monograph   Indications Alve is indicated in- Irritable Bowel Syndrome Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease) Abdominal pain associated with menstrual periods (Primary dysmenorrhea) Relief of other conditions associated with spasm of involuntary muscle *       ' Pharmacology Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine\\n\\nCitrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea). Dosage & Administration Adult: Orally: 60-120 mg 1-3 times daily. *       ' Interaction There are no drug interactions reported with this medicine. Contraindications Paralytic ileus or known hypersensitivity to any of the ingredients. Side Effects Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions. Pregnancy & Lactation Although no teratogenic effects have been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited. Precautions & Warnings Avoid Alve in patients with intestinal obstruction or paralytic ileus. Use in Special Populations Children under 12 years: Not recommended Overdose Effects Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension. Therapeutic Class Anticholinergics Storage Conditions Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25C temperature. Pack Image: Alve 60 mg Tablet\"), -0.13551879100026354), (Document(id='25928c4a-6d68-4c9d-aafb-1107a69ed839', metadata={}, page_content=\"first trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nG-Antacid Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide 250 mg+500 mg Gonoshasthaya Pharma Ltd. Unit Price:  0.50 (25 x 10:  125.00) Strip Price:  5.00 Alternate Brands Innovator's Monograph   Indications Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach & dyspepsia. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3 47%, minimum): 250 mg Magnesium Hydroxide BP: 400 mg\\n\\nEach 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 175 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 225 mg Pharmacology This drug is well-balanced combination of essential non-systemic antacids which excel in efficacy and palatability. These are dependable antacid preparations without acid rebound, constipating or cathertic effects. Both the preparations provide symptomatic relief of hyperacidity associated with heartburn, acid ingestion or sour stomach.Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation. Dosage & Administration Tablet: Two tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician. *       ' Interaction G-Antacid inhibits the absorption of following drugs: Azithromycin, cefpodoxime, ciprofloxacin, isoniazid, rifampicin, norfloxacin, ofloxacin, pivampicillin, tetracyclines, Gabapentin and phenytoin, Itraconazole, ketoconazole, Chloroquine, hydroxychloroquine and Phenothiazines. Contraindications This is contraindicated in hypophosphataemia. It is also contraindicated in alkalosis and hypermagnesaemia where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Long term use of any antacid results in alkaluria, which may predispose to nephrolithiasis by forming precipitation of calcium phosphate. Pregnancy & Lactation It is advised to avoid antacid preparations in the first trimester of pregnancy. Precautions & Warnings Antacids reduce the absorption of tetracycline when given concomitantly. These should not be used concomitantly Therapeutic Class Antacids Storage Conditions Keep below 30C temperature, away from light\\n\\n& moisture. Keep out of the reach of children.\"), -0.14928302449325437), (Document(id='38b52da7-258f-4a7a-8404-0dd73d75ca82', metadata={}, page_content=\"first trimester of pregnancy. Precautions & Warnings This should be used with caution in\\n\\npatients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\\n\\ntemperature, away from light & moisture. Keep out of the reach of children.\\n\\nG-Antacid Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide 250 mg+500 mg Gonoshasthaya Pharma Ltd. Unit Price:  0.50 (25 x 10:  125.00) Strip Price:  5.00 Alternate Brands Innovator's Monograph   Indications Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach & dyspepsia. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3 47%, minimum): 250 mg Magnesium Hydroxide BP: 400 mg\\n\\nEach 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 175 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 225 mg Pharmacology This drug is well-balanced combination of essential non-systemic antacids which excel in efficacy and palatability. These are dependable antacid preparations without acid rebound, constipating or cathertic effects. Both the preparations provide symptomatic relief of hyperacidity associated with heartburn, acid ingestion or sour stomach.Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation. Dosage & Administration Tablet: Two tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician. *       ' Interaction G-Antacid inhibits the absorption of following drugs: Azithromycin, cefpodoxime, ciprofloxacin, isoniazid, rifampicin, norfloxacin, ofloxacin, pivampicillin, tetracyclines, Gabapentin and phenytoin, Itraconazole, ketoconazole, Chloroquine, hydroxychloroquine and Phenothiazines. Contraindications This is contraindicated in hypophosphataemia. It is also contraindicated in alkalosis and hypermagnesaemia where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Long term use of any antacid results in alkaluria, which may predispose to nephrolithiasis by forming precipitation of calcium phosphate. Pregnancy & Lactation It is advised to avoid antacid preparations in the first trimester of pregnancy. Precautions & Warnings Antacids reduce the absorption of tetracycline when given concomitantly. These should not be used concomitantly Therapeutic Class Antacids Storage Conditions Keep below 30C temperature, away from light\\n\\n& moisture. Keep out of the reach of children.\"), -0.14928302449325437), (Document(id='c619ae2c-c0c4-4fc4-bc73-7d2957781986', metadata={}, page_content=\"temperature, away from light & moisture. Keep out of the reach of children.\\n\\nNeutral S Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 200\\n\\nmg+200 mg+30 mg Hallmark Pharmaceuticals Ltd. Unit Price:  0.79 (200's pack:  158.00) Also available as: (200 mg+400 mg+30 mg)/5 ml (Suspension) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg Each 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 200 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 400 mg Simethicone USP: 30 mg Pharmacology This is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled.This is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. Dosage & Administration Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. *       ' Interaction All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. Contraindications This should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are\"), -0.16239566770826652), (Document(id='52faae4d-f7c3-431b-9671-78a3cf85a9e9', metadata={}, page_content=\"temperature, away from light & moisture. Keep out of the reach of children.\\n\\nNeutral S Chewable Tablet Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 200\\n\\nmg+200 mg+30 mg Hallmark Pharmaceuticals Ltd. Unit Price:  0.79 (200's pack:  158.00) Also available as: (200 mg+400 mg+30 mg)/5 ml (Suspension) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg Each 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 200 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 400 mg Simethicone USP: 30 mg Pharmacology This is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled.This is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. Dosage & Administration Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. *       ' Interaction All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. Contraindications This should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are\"), -0.16239566770826652)]\n",
      "  self.vectorstore.similarity_search_with_relevance_scores(\n"
     ]
    }
   ],
   "source": [
    "response=chain.invoke(\"should i CONTINUE NAPA for fever?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "b0d96bf9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Okay, lets analyze the information provided to address the users question: Should I CONTINUE NAPA for fever?\n",
      "\n",
      "**Heres my assessment based on the provided text:**\n",
      "\n",
      "*   **The Users Query is Misinterpreted:** The user is asking about continuing *NAPA* for a fever. However, the text primarily discusses *Ambroxol Hydrochloride* (in Acorex syrup) and *Eromycin 3% Lotion*. There is no mention of \"NAPA\" in the provided documentation.\n",
      "\n",
      "*   **Ambroxol Hydrochloride (Acorex) is Relevant for Fever Symptoms:** Acorex, containing Ambroxol Hydrochloride, *is* indicated for productive cough, which is a common symptom of fever and respiratory infections. Its a mucolytic agent designed to help loosen and expel mucus, which can be beneficial when a fever is accompanied by a cough.\n",
      "\n",
      "*   **Important Considerations & Warnings:**\n",
      "    *   **Dont Combine with Antitussives:** The text explicitly warns against taking Acorex simultaneously with antitussives like Codeine.  If phlegm is liquefied by Acorex, the expectoration might not occur, rendering the medication ineffective.\n",
      "    *   **Caution with Ulcers/Convulsions:**  Patients with gastric/duodenal ulcers or convulsive disorders should use Acorex cautiously.\n",
      "    *   **Allergic Reactions:**  Rarely, allergic responses (eruption, urticaria, angioneurotic edema) can occur.\n",
      "\n",
      "**Recommendation:**\n",
      "\n",
      "Given the information provided, **it *might* be appropriate to continue using Acorex (Ambroxol Hydrochloride) for a fever *if* the fever is accompanied by a productive cough.** However, this recommendation is contingent on the following:\n",
      "\n",
      "1.  **Confirm the Diagnosis:** Ensure the fever is due to a respiratory infection and not another condition.\n",
      "2.  **Avoid Antitussives:** Do not take Acorex with any cough suppressants.\n",
      "3.  **Consult a Healthcare Professional:** *Crucially*, the user should consult a doctor or pharmacist for a proper diagnosis and personalized advice.  Self-treating a fever can be risky.\n",
      "\n",
      "**Disclaimer:** *I am an AI Chatbot and not a medical professional. This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment.*\n",
      "\n",
      "Do you want me to elaborate on any specific aspect of this response, such as the mechanism of action of Ambroxol, or potential side effects?\n"
     ]
    }
   ],
   "source": [
    "print(response)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "id": "1c249f0c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entacyd Plus Chewable Tablet Pack Image Aluminium Hydroxide + Magnesium Hydroxide + Simethicone 400 mg+400 mg+30 mg Square Pharmaceuticals PLC Unit Price:  2.50 (20 x 10:  500.00) Strip Price:  25.00 Also available as: (200 mg+400 mg+30 mg)/5 ml (Suspension) Alternate Brands Indications This is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. This rapidly relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. *       ' Composition Each tablet contains- Dried Aluminium Hydroxide Gel BP (Al2O3, 47% minimum): 425.53 mg Magnesium Hydroxide BP: 400 mg Simethicone USP: 30 mg\n",
      "\n",
      "Simethicone USP: 30 mg Each 5 ml contains- Aluminium Oxide (Equivalent amount of Aluminium Hydroxide Gel USP): 200 mg Magnesium Hydroxide (Equivalent amount of Magnesium Hydroxide Paste USP): 400 mg Simethicone USP: 30 mg Pharmacology This is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled.This is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. Dosage & Administration Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician.Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. *       ' Interaction All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. Contraindications This should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Side Effects Gastrointestinal side effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. Pregnancy & Lactation It is advised to avoid antacid preparations in the first trimester of pregnancy. Precautions & Warnings This should be used with caution in patients with kidney disease. Therapeutic Class Antacids Storage Conditions Keep below 30C\n"
     ]
    }
   ],
   "source": [
    "from IPython.display import HTML, display\n",
    "\n",
    "\n",
    "def plt_img_base64(img_base64):\n",
    "    # Create an HTML img tag with the base64 string as the source\n",
    "    image_html = f'<img src=\"data:image/jpeg;base64,{img_base64}\" />'\n",
    "\n",
    "    # Display the image by rendering the HTML\n",
    "    display(HTML(image_html))\n",
    "\n",
    "\n",
    "docs = retriever.invoke(\"Entacyd \", k=1)\n",
    "for doc in docs:\n",
    "    if is_base64(doc.page_content):\n",
    "        plt_img_base64(doc.page_content)\n",
    "    else:\n",
    "        print(doc.page_content)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
